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INTRODUCTION 
 
This thesis describes investigations that were performed to gain more insight into the 
role of Chlamydia (C.) pneumoniae in relation to atherosclerosis. In this introduction the 
current knowledge of the pathogenesis of atherosclerosis, the role of C. pneumoniae, 
and the effects of antibiotic treatment are described. 
 
Atherosclerosis 
Atherosclerosis is a major cause of morbidity and mortality in both industrialised and 
developing countries, with a broad spectrum of clinical manifestations. In the year 2000 
for example, coronary heart disease caused more than 1 of every 5 deaths in the United 
States and was therefore the leading cause of death among men and women. Acute 
myocardial infarction was diagnosed in 540.000 Americans in the same year1. 
Atherosclerosis is also a major cause of physical disability, particularly in the rapidly 
growing population of elderly persons2,3. The prevention of coronary events and the 
maintenance of physical functioning are major challenges in preventive care. 
The process of atherogenesis begins at an early age4. The earliest type of lesion, 
the so-called fatty streak, is common in infants and young children5. The fatty streak is a 
pure inflammatory lesion6, consisting of monocyte-derived macrophages and specific 
subtypes of T-lymphocytes. The initiation of atherosclerosis is characterized by 
remodeling of the arterial intima. The arterial wall thickens, which is compensated by 
gradual dilation, while monocytes and macrophages accumulate. This is accompanied 
by the release of hydrolytic enzymes, cytokines, chemokines, and growth-factors. As the 
atherogenesis process advances, foam-cells are formed by accumulation of cholesterol 
in macrophages. Finally an advanced and complicated lesion evolves: the fibrous 
plaque. In this phase the artery can no longer compensate by dilatation. The endothelial 
surface of the lesion is damaged; the plaque becomes vascularized leading to 
hemorrhage and thrombosis formation. Finally the artery can become completely 
obstructed. 
Research on the pathogenesis of atherosclerosis has focused for decades on 
several now well known risk factors, which include smoking, hypercholesterolaemia, 
diabetes mellitus, hypertension, and a positive family history of cardiovascular disease. 
However, these risk factors do not fully account for all cardiovascular patients. Up to 
30% of patients presenting with myocardial infarction for example have none of these 
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risk factors7. Furthermore, in some populations, the marked frequency of classical risk 
factors is not associated with a high prevalence of cardiovascular disease8. Therefore 
the search for novel potential risk factors continues. 
The hypothesis that atherosclerosis may be a 'response-to-injury' was postulated 
more than a century ago by Von Rokitansky9 and Virchow10. The involvement of 
inflammatory response including inflammatory cells (macrophages and T lymphocytes) 
and cytokines in all stages of the atherosclerotic process suggests a central role for 
inflammation in atherosclerosis11. The idea of infections playing a role was proposed 
over a century ago by investigators in Europe, but was championed in North America by 
Osler12 and Billings13 in the early part of last century. However, evidence that infection 
might induce atheromatous change was not found until the 1970’s, when Fabricant et al. 
infected germ-free chickens with an avian herpesvirus, producing arterial lesions that 
resembled atherosclerosis in humans14. Since then, a number of microbes have been 
implicated in the etiology of atherosclerosis, including C. pneumoniae.  
 
Chlamydia pneumoniae 
Chlamydiae were originally classified in the order Chlamydiales, with only one family, the 
Chlamydiaceae, and one genus, Chlamydia. This genus contained four species: C. 
pecorum, C. psittaci, C. trachomatis, and C. pneumoniae. Recently a new classification 
is proposed based on DNA sequence analysis by Everett et al.15 (figure 1). In this 
reclassification the family Chlamydiaceae, is divided into two genera, Chlamydia and 
Chlamydophila. Two new species, Chlamydia muridarum and Chlamydia suis, are added 
to Chlamydia trachomatis in the genus Chlamydia. Chlamydophila contains the current 
species Chlamydophila pecorum, Chlamydophila pneumoniae and Chlamydophila 
psittaci. Three new Chlamydophila species are derived from Chlamydia psittaci: 
Chlamydophila abortus, Chlamydophila caviae, and Chlamydophila felis. Furthermore, 
three new non Chlamydiaceae families have been added, Simikaniaceae, 
Parachlamydiaceae, and Waddliaceae. An impressive number of eminent 
chlamydiologists, are opposed to the new classification and their objections were 
published in a letter16. The main criticisms were that there is insufficient reason to divide 
the former Chlamydiaceae into 2 new genera and that it had taken a long time to get 
clinicians used to Chlamydia and would be confusing for them. In this thesis the old 
classification name Chlamydia pneumoniae was used, to prevent confusion.   
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Figure 1. The new classification of the order Chlamydiales.  
 
Order Family Genus Species 
    
Chlamydiales    
 Chlamydiaceae   
  Chlamydia  
   trachomatis 
   suis 
   muridarum 
    
  Chlamydophila  
   pneumoniae 
   psittaci 
   abortus 
   felis 
   caviae 
   pecorum 
    
 Simkaniaceae   
  Simkania  
   negevensis 
    
 Parachlamydiaceae   
  Parachlamydia  
   acanthamoeba 
  Neochlamydia  
   hartmanellae 
    
 Waddliaceae   
  Waddlia  
   chondrophila 
 
 
C. pneumoniae has been recognized as a human pathogen since 1986 and is 
now known to be a common cause of respiratory tract infection, causing bronchitis, 
sinusitis, pharyngitis and accounts for over 5% of all cases of community-acquired 
pneumonia17. Infection is usually associated with relatively mild disease. In addition to 
the acute manifestations of infection, C. pneumoniae has been implicated as an 
etiological agent in the development of several chronic diseases. Besides 
atherosclerosis, also adult-onset asthma and multiple sclerosis are mentioned18,19. 
C. pneumoniae, C. trachomatis, and C. psittaci are known to cause disease in 
humans. Unlike C. trachomatis, C. pneumoniae is not transmitted sexually and unlike C. 
psittaci, it has no animal reservoir20. Humans are the only known reservoir of C. 
pneumoniae.  
Like all Chlamydiaceae, C. pneumoniae is an obligate intracellular organism. The 
presence of a lipopolysaccharide cell wall, DNA and RNA, and the ability of the 
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organisms to replicate by binary fusion classify them as Gram-negative bacteria21. Their 
developmental life cycle occurs in the cytoplasm of a host cell. The life cycle of all 
chlamydiae has two distinct phases: a smaller extracellular non-replicating infectious 
phase called elementary body (EB) and a larger intracellular non-infectious replicating 
phase, called reticular body (RB). After attachment to host cells, elementary bodies enter 
the cell, probably by endocytosis, and differentiate into reticulate bodies. Reticulate 
bodies replicate, using the host cell energy, and form inclusions. Prior to cell lysis and 
release from the host cell reticular bodies retransform into elementary bodies22. This 
biphasic life cycle lasts for 48 to 72 hours. 
Different C. pneumoniae isolates have 94 to 100% DNA homology with each 
other but less then 10% with C. trachomatis or C. psittaci23. Furthermore, elementary 
bodies of C. pneumoniae are pear-shaped, with a large periplasmic space, clearly visible 
on electron microscopy (figure 2), whereas the elementary bodies of C. trachomatis, C. 
psittaci and C. pecorum are apple-shaped. 
 
Figure 2. Elementary body of Chlamydia pneumoniae visible on electron microscopy (x80.000). 
 
Most of our current understanding of the epidemiology of C. pneumoniae 
infection derives from serologic studies using the microimmunofluorescence assay 
(MIF). These studies indicate that C. pneumoniae infection is common throughout the 
world. Seropositivity is low in early childhood (< 5 years), rising rapidly during school 
years. At the age of 20 years, approximately 50% of individuals will have detectable 
antibodies. Seroprevalence continues to rise, albeit at a slower pace, in adulthood and 
reaches 75% in the elderly population20,22. This high antibody prevalence in later life 
suggests that reinfection with the organism is common. Seroprevalence is approximately 
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equal in both sexes at < 15 years of age, but seropositivity rates in adults are higher in 
men than in women. 
While C. pneumoniae infection is an endemic disease, local epidemics are 
described in nursing homes24, schools25, and military institutions26,27. There is no clear 
seasonal variation in disease, but retrospective serological studies suggest that 
community-wide epidemics occur in 4-6 year cycles28,29. 
Clinical manifestations of C. pneumoniae infection range from asymptomatic to 
mild disease, and very rarely severe life threatening infection occurs. Pneumonia and 
bronchitis are the most frequently observed manifestations of C. pneumoniae infection. 
Multiple studies have shown that C. pneumoniae is responsible for 5-20% of cases of 
community-acquired pneumonia (CAP). 
Diagnosis of C. pneumoniae infections remains difficult. Several techniques are 
currently employed:  
Serologic testing. The MIF test is considered to be the standard serologic assay for 
determination of Chlamydia seropositivity30. The test is able to differentiate among the 
IgG, IgA, and IgM antibody classes. However, it has some major drawbacks: it is time-
consuming and requires a very experienced microscopist for interpretation of the slides. 
Furthermore, the specificity of MIF has been questioned, as cross-reactions among the 
major outer membrane proteins of different Chlamydia species were reported31,32. 
Because of these problems related to MIF, enzyme-linked immunosorbent assays 
(ELISAs) and enzyme immunoassays (EIAs) were commercially developed; they are 
relatively simple to perform, are less time-consuming, are more objective because of the 
photometrical reading of the results, and are easier to standardize.  
Isolation. C. pneumoniae can be isolated in cell culture. The organism is fastidious and 
slow growing. Therefore isolation is not usually attempted for documentation of infection 
in the clinical setting but can be useful for research purposes. However, primary isolation 
from clinical specimens like atheromatous lesions is very difficult. 
In addition, direct detection of organisms is possible by electron microscopy (EM), 
immunohistochemistry (IHC) staining, and polymerase chain reaction (PCR).  
IHC staining. Antigen detection methods with use of genus- or species-specific 
antibodies labeled with peroxidase or a fluorescent marker are commonly used to 
identify Chlamydia in tissue. Like EM, these techniques may allow localization of the 
organisms in specific cells and areas. Considerable difficulty has been experienced with 
IHC because of non-specific background staining. 
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PCR testing. PCR techniques using various C. pneumoniae-specific primers have been 
developed and used for detection of the organism in pharyngeal swabs, bronchoalveolar 
lavage, and sputum specimens. Compared to cell culture PCR is much more sensitive 
and highly specific. It has the potential to detect a single organism. This method has also 
been used to detect C. pneumoniae in pathologic tissue specimens. However, to date, 
there are no standardized PCR or other nucleic acid amplification methods for the 
detection of C. pneumoniae. 
Erythromycin, tetracycline, and doxycycline are active in vitro against C. 
pneumoniae and are recommended as first-line therapeutic agents. Newer macrolides, 
like clarithromycin, are also active in-vitro and achieve high intracellular concentrations. 
These agents are better tolerated than erythromycin and therefore may be considered 
as either first-line agents or as alternatives to erythromycin and the tetracyclines for 
treatment of infections believed to be due to C. pneumoniae. The organism is not 
susceptible to penicillin, ampicillin, or sulfa drugs33.  
 
The link between atherosclerosis and C. pneumoniae 
The initial study indicating a potential link between atherosclerosis and C. pneumoniae 
infection was performed in Finland and showed that patients with coronary artery 
disease (CAD) were more likely to have detectable antibodies to C. pneumoniae34. This 
study examined sera from 40 men with acute myocardial infarction (AMI), 30 men with 
CAD and 41 matched controls. Serologic evidence of previous infection (C. pneumoniae-
specific IgG>128 and/or IgA>32) was found in 68% of patients with AMI (OR 11.92, 
95%CI 3.65 - 40.91), 50% with chronic CAD (OR 4.86, 95%CI 1.46 - 16.67) and in only 
17% of population-matched controls. Since this initial report, several investigators from 
various countries have confirmed these seroepidemiological findings. 
In 1993 Shor, a South African pathologist, noticed unusual pear-shaped 
structures in coronary artery atheroma on scanning electron microscopy of autopsy 
specimens. Using IHC and PCR techniques, Shor and the study group of Grayston were 
able to confirm that these structures were the elementary bodies (EB) of C. 
pneumoniae35,36. Since then, morphologic and microbiologic evidence for the presence 
of C. pneumoniae has been found in a wide variety of diseased arteries. The organism 
was identified in vascular tissue from patients with cardiovascular disease by electron 
microscopy, PCR, and IHC. Sporadically, C. pneumoniae has also been isolated by 
culture from atheromatous vascular specimen by some investigators: reports of isolation 
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from a carotid endarterectomy specimen, the coronary artery of a recipient’s heart 
removed prior to heart transplantation, and, in one report, coronary artery specimens 
from 16% (11/70) of patients undergoing coronary artery bypass graft surgery37-39. 
More direct evidence of causality as well as insight into potential pathogenic 
mechanism was provided by animal experimental models. Results of studies using 
ApoE-deficient knockout mice, which spontaneously develop atherosclerosis on a 
normal diet, indicated that C. pneumoniae can be detected in aortic plaque specimen 
after intranasal inoculation. C. pneumoniae seems to disseminate systematically after 
respiratory infection, and the organism persists in aortic plaque for at least 20 weeks 
following infection. The infection appears to accelerate the progression of the 
atherosclerotic process in these animals. Studies in New Zealand white rabbits, which do 
not typically develop atherosclerosis on a normal diet, found that animals infected 
intranasally with C. pneumoniae later showed changes in the aorta consisting of intimal 
thickening or fibrolipid plaques, and that C. pneumoniae could be detected in those 
plaque specimens by IHC studies40-43. 
In another study in New Zealand white rabbits, which were fed a slightly 
cholesterol-enhanced diet to enhance atherosclerotic lesion development, were 
inoculated intranasally with either C. pneumoniae or saline. The animals were 
randomized to a 7-week course of treatment with azithromycin or to no treatment. 
Infected, untreated animals had significantly larger areas of plaque involvement of the 
thoracic aorta than those seen in uninfected controls. In contrast, the infected and 
treated rabbits did not demonstrate this increase. This suggests that treatment with 
azithromycin might prevent the infection-induced acceleration in atherosclerosic plaque 
development44.  
On the basis of these results, it was anticipated that infection with C. pneumoniae 
might prove a novel treatable risk factor for atherosclerosis, with relevance comparable 
to that of Helicobacter pylori in peptic ulcer disease45.  
In 1997, Gupta and colleagues46 published the results of a small clinical trial in 60 
survivors of acute myocardial infarction that had persistently elevated anti-C. 
pneumoniae IgG titers ((MIF) >1:64). These individuals had been randomized to receive 
a 3-day course of azithromycin (500mg/d), two such courses 3 months apart, or placebo. 
Patients who received azithromycin showed a reduction in acute coronary events from 
28% to 8% compared to those who received placebo (p=0.04, RR 0.27, 95% CI 0.06 - 
0.95), but there was no additional benefit in receiving an additional course of therapy. 
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The results of this trial generated considerable interest and encouraged further studies 
on the relation of C. pneumoniae and atherosclerosis.  
 
Outline of this thesis 
To gain more insight in the association between C. pneumoniae and atherosclerosis, we 
initiated several projects. 
 Laboratory techniques play a crucial role in studies of the association of C. 
pneumoniae and atherosclerosis. Therefore, the diagnostic assays were first validated. 
Because discrepancies between results of different detection methods are often 
reported, the correlation between two frequently used detection methods for C. 
pneumoniae, i.e. PCR and IHC, is assessed in chapter 2. To optimise the detection of C. 
pneumoniae by PCR, four procedures for C. pneumoniae-DNA extraction from vascular 
tissue were evaluated, with respect to the yield of recovered DNA. The results are 
presented in chapter 3. 
Up to now no studies have been reported in which the effect of treatment on the 
presence of C. pneumoniae in vascular tissue was investigated. In a placebo-controlled, 
double blind, randomised intervention trial, we investigated whether C. pneumoniae 
could be eradicated from vascular tissue by a short course of clarithromycin. The effect 
of claritrhomycin was evaluated by IHC, real time PCR and LCx PCR (chapter 4). 
Stabilisation of atherosclerotic plaques might be achieved by any anti-inflammatory 
treatment regimen. There is much speculation about the anti-inflammatory potential of 
macrolides, in particular of clarithromycin, independently of their established role as 
antimicrobial agents. Therefore, the effect of clarithromycin on inflammatory markers is 
studied in chapter 5. Because it has been hypothesized that antibiotic treatment effective 
against C. pneumoniae might lower the risk for further cardiac events in patients with 
severe atherosclerosis, the effect of treatment with clarithromycin prior to cardiac surgery 
on clinical outcome and prognosis was determined in a two-year follow-up of these 
patients (chapter 6). 
The use of macrolide antibiotics like clarithromycin raises serious concern about 
the development of macrolide resistance. Resistance to macrolide antibiotics, like 
clarithromycin, is indeed increasing. Therefore, the effect of clarithromycin on the 
development of resistance in the oropharyngeal and nasopharyngeal flora in the patients 
described in chapter 7 was quantified (Chapter 7). 
 Finally, in chapter 8 the summary and conclusions are presented. 
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SUMMARY 
 
Polymerase chain reaction (PCR) and immunohistochemistry (IHC) have been used to 
detect Chlamydia (C.) pneumoniae in vascular tissues. Discrepancies between the 
results of these two methods have frequently been reported. However, the correlation 
between PCR and IHC has not been analyzed yet. This study assesses the correlation 
between the detection of C. pneumoniae by PCR and IHC in 45 atherosclerotic and 50 
non-atherosclerotic tissues specimens. Also, the presence of Mycoplasma (M.) 
pneumoniae in these 95 specimens was investigated. Correlation was found between 
the detection of C. pneumoniae by PCR and IHC in the atherosclerotic tissues. Both 
tests were positive in 10 specimens and negative in 17 specimens (p=0.003). There was 
no significant correlation between PCR and IHC in non-atherosclerotic specimens 
(p=ns). M. pneumoniae was detected, by PCR, in one atherosclerotic specimen. The 
results show correlation between PCR and IHC in the detection of C. pneumoniae in 
atherosclerotic tissues and support the specificity of the association between C. 
pneumoniae and atherosclerosis. 
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INTRODUCTION  
 
Using polymerase chain reaction (PCR) and immunohistochemistry (IHC), the 
presence of Chlamydia (C.) pneumoniae has been demonstrated in atherosclerotic 
tissues, but in control vascular tissues this pathogen has been found less frequently1. 
These findings indicate that C. pneumoniae may play a role in the pathogenesis of 
atherosclerosis.  
In addition to C. pneumoniae, several microorganisms have been postulated as 
possible risk factors for atherosclerosis2,3. The association between atherosclerosis and 
both cytomegalovirus and Helicobacter pylori has been extensively studied2. However, 
till now only one report on the presence of Mycoplasma (M.) pneumoniae in vascular 
tissues has been generated4.  
The microimmunofluorescence test (MIF), PCR and IHC have been used to 
explore the association between C. pneumoniae and atherosclerosis. Discrepancies 
among the results obtained by these methods have frequently been found5-7. Nothing, 
however, is known about the correlation between the results of these detection methods.  
The present study assesses the correlation between the detection of C. 
pneumoniae by PCR and IHC. Also, the correlation between C. pneumoniae serology 
and the detection of this pathogen, by PCR and IHC, in vascular tissue specimens was 
analyzed. M. pneumoniae-PCR was performed to detect M. pneumoniae in athero-
sclerotic and non-atherosclerotic tissues. 
 
 
MATERIALS AND METHODS 
 
Specimens were collected from 95 patients undergoing cardiac surgery. Forty-
five atherosclerotic specimens and 50 non-atherosclerotic tissue specimens (aortic-
punchs) were collected. Each specimen was divided into two portions; one for PCR and 
one for IHC. The PCR portion was transported to the laboratory in a Tris-EDTA buffer 
containing 0.5% sodium dodecyl sulfate. In the laboratory, specimens were stored at 
minus 200C. The IHC portion was fixed in 10% phosphate-buffered formalin. In addition, 
sera were obtained from all patients to measure the level of IgG antibodies against C. 
pneumoniae. Specimens were evaluated blind. Patients were not examined to assess 
the presence of C. pneumoniae clinical disease. 
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Polymerase chain reaction 
DNA extraction from specimens was performed using the QiAmp DNA minikit 
(Qiagen, CA, USA). For the PCR template, 5 µL of 200 µL elution sample was used.  
Detection of C. pneumoniae DNA was carried out by 16S rRNA gene-based 
PCR, using the primers CpnA: 5’-TGA CAA CTG TAG AAA TAC AGC-3’ and CpnB: 5’-
CGC CTC TCT CCT ATA AAT-3’ as described previously8.  
Detection of M. pneumoniae was performed by PCR assay based on the P1 
adhesin gene using the primers Pn1: 5’-GCC ACC CTC GGG GGC AGT CAG-3’ and 
Pn2: 5’-GAG TCG GGA TTC CCC GCG GAG G-3’ as described previously4,9. 
To minimize the risk of contamination, strict PCR-anti-contamination precautions, 
such as the use of UDG/dUTP, were taken to prevent carry-over of previous PCR 
reactions. Sample processing and the PCR assay were performed in separate rooms 
and a negative control was processed with every 5 samples. To control for inhibition of 
the PCR reaction, a second sample of each specimen was spiked with target DNA (C. 
pneumoniae or M. pneumoniae). Inhibited PCR samples were retested using 2.5 µL of 
specimen. PCR products were visualized after electrophoresis in 2% ethidium bromide-
stained agarose gels.  
To confirm positive results, 3 µL of the PCR product was spotted and hybridized, 
with the 21 bp 5’-biotinylated probe Cpneu-B:5’ GAC ACA CGT ACA ATG GTT-3’ in the 
case of C. pneumoniae-PCR and with the 5’-biotinylated probe MP2-B: 5’-GGT GAA 
GGA ATG ATA AGG CT-3’ in the case of M. pneumoniae-PCR. Hybridization signals 
were visualized using streptavidin-peroxidase and ECL detection reagents (Amersham, 
UK). 
 
Immunohistochemistry   
Specimens were transported in 10% phosphate buffered formalin. Subsequently 
tissues were, in some cases after decalcification with EDTA, embedded in paraffin and 
sectioned at 5 µm. IHC staining was performed according to methods previously 
described10. Sections were stained with a mouse anti-C. pneumoniae (TW 183) 
monoclonal antibody (DAKO Diagnostics, Denmark). C. pneumoniae-infected HL cells 
and a tissue section stained with normal mouse ascites were used as a positive and a 
negative control, respectively. Positive and negative controls were run with each batch of 
specimens. 
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Microimmunofluorescence test  
C. pneumoniae (TW 183) IgG antibodies in the sera were determined using a 
microimmunofluorescence test (MRL Diagnostics, CA) as described previously11,12. An 
IgG antibody titer > 1:16 was considered positive. All serologic tests were performed 
blind by the same technician.  
 
Statistical analysis 
Correlation between the results of the different assays was analyzed by the 
Cohen’s Kappa test.  
 
 
RESULTS 
 
Atherosclerotic specimens were obtained from 38 males and 7 females (mean 
age 63 years, range 41-86). Non-atherosclerotic lesions were obtained from 41 males 
and 9 females (mean age 65 years, range 44-79). 
Forty-five atherosclerotic tissue specimens and 50 non-atherosclerotic tissue 
specimens were available for the PCRs assays. Specimens for IHC assay were obtained 
at the same time from all patients, but 3 atherosclerotic specimens and 4 non-
atherosclerotic specimens were missed. Blood samples for C. pneumoniae serology 
were available from 91 patients (41 in the atherosclerotic group and 50 in the non- 
atherosclerotic).  
C. pneumoniae DNA was detected by PCR in 22% (10/45) of the atherosclerotic 
specimens and in 10% (5/50) of non- atherosclerotic specimens. IHC staining was 
positive for C. pneumoniae in 60% (25/42) of the atherosclerotic specimens and in 9% 
(4/46) of the non-atherosclerotic specimens. The correlation between the detection of C. 
pneumoniae by PCR and IHC is shown in table 1. There was a correlation between the 
detection of C. pneumoniae by PCR and IHC in the atherosclerotic specimens 
(p=0.003). A poor correlation was found between the results obtained by PCR and IHC 
in the non-atherosclerotic specimens (p=ns).  
The MIF test detected C. pneumoniae IgG antibodies in 88% (36/41) of patients 
in the atherosclerotic group and in 96% (48/50) of patients in the non- atherosclerotic 
group. Table 2 demonstrates the correlation between C. pneumoniae serology and the 
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results obtained by either PCR and IHC. There was no significant correlation between C. 
pneumoniae serology and both PCR and IHC.  
 
Table 1. Correlation between polymerase chain reaction (PCR) and immunohistochemistry (IHC) 
in the detection of C. pneumoniae in atherosclerotic and non-atherosclerotic tissue specimens. 
 atherosclerotic specimens non-atherosclerotic specimens 
 IHC negative IHC positive IHC negative IHC positive 
PCR negative, n 17 15 38 4 
PCR positive, n 0 10 4 0 
Correlation, Kappa  
(p value) 
0.35 
(0.003) 
0.1 
(ns) 
 
 
Table 2. Correlation between serology (MIF), polymerase chain reaction (PCR) and 
immunohistochemistry (IHC) results.  
atherosclerotic specimens    
 PCR negative PCR positive IHC negative IHC positive 
MIF negative, n 5 0 2 2 
MIF positive, n 26 10 12 22 
Correlation, Kappa  
(p value) 
0.1 
(ns) 
0.07 
(ns) 
non-atherosclerotic specimens    
 PCR negative PCR positive IHC negative IHC positive 
MIF negative, n 1 1 2 0 
MIF positive, n 44 4 40 4 
Correlation, Kappa  
(p value) 
0.04 
(ns) 
0.01 
(ns) 
 
 
M. pneumoniae was detected by PCR in one atherosclerotic tissue specimen. All 
non-atherosclerotic specimens were M. pneumoniae-negative. 
 
 
DISCUSSION 
 
This study shows the following features: there was correlation between PCR and 
IHC in the detection of C. pneumoniae in atherosclerotic tissues, but a poor correlation 
was found in non-atherosclerotic specimens. The MIF test was not correlated with the 
results of PCR or IHC. M. pneumoniae was detected in one atherosclerotic specimen. All 
non-atherosclerotic specimens were M. pneumoniae-negative. 
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Table 3. Correlation between polymerase chain reaction (PCR) and immunohistochemistry (IHC) 
in 10 studies in which arterial tissues were investigated. 
Reference Material No PCR+
 a 
& IHC+ 
PCR-b 
& IHC- 
PCR+ 
& IHC- 
PCR- 
& IHC+ 
Correlation, 
Kappa  
(p value) 
Campbell et al. 
1995 
Coronary 
atheromas 38 9 18 3 8 0.4 (0.01) 
Jackson et al. 
1997a 
Coronary 
arteries 38 1 25 5 7 0.05 (0.8) 
Kuo et al. 
1993b 
Coronary 
atheromas 30 8 14 5 3 0.45 (0.01) 
Shor et al. 
1998 
Arterial 
atheromas 7 2 4 0 1 0.7 (0.05) 
Kuo et al. 
1997 
Peripheral 
arteries 17 2 9 0 6 0.3 (0.1) 
Juvonen et al. 
1997 AAA
c 9 5 3 1 0 0.8 (0.02) 
Jackson et al. 
1997b 
Carotid 
endarterectomy 16 3 8 0 5 0.4 (0.055) 
Ramirez 
1996 
Coronary 
arteries 12 3 5 2 2 0.3 (0.3) 
Kuo et al. 
1995 
Coronary 
arteries 49 2 41 1 5 0.3 (0.007) 
Davidson et al. 
1998 
Coronary 
arteries 60 12 38 2 8 0.6 (<0.001) 
a + Positive; b – Negative; c AAA; abdominal aortic aneurysms 
 
Several studies have reported a wide variation in the detection rate of C. 
pneumoniae between PCR and IHC5,7. In general, more positive results are obtained 
with IHC than PCR. This was also the case in the present study. It has been suggested 
that these discrepancies might reflect differences in the sensitivity and specificity of the 
two methods1. Focal localization of C. pneumoniae in vascular tissues and the presence 
of components that inhibit PCR may influence the results of IHC and PCR7. However, 
discrepancy between detection rates of C. pneumoniae by PCR and IHC does not imply 
that there is no correlation between these methods. In this study, with regard to the 
atherosclerotic tissues there was correlation between the results of IHC and PCR, but no 
such correlation was found in non-atherosclerotic specimens. We can not explain why no 
correlation was found in non-atherosclerotic tissues. A possible explanation is that after 
initial infection, C. pneumoniae does not persist in non-atherosclerotic tissues6. We 
analyzed the correlation between PCR and IHC in 10 studies in which these methods 
were used to detect C. pneumoniae in arterial tissues6,13-21. Correlation between PCR 
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and IHC results was found in 7 studies (Table 3). Our findings together with previous 
report provide evidence that the results of PCR and IHC are correlated. 
In the present study no correlation was found between C. pneumoniae serology 
and the detection of C. pneumoniae either by PCR and IHC. Controversial reports have 
been published on the association between C. pneumoniae serology and the detection 
of the pathogen in vascular tissues22. In 7 studies in which C. pneumoniae IgG 
antibodies were determined and PCR was used to detect C. pneumoniae in arterial 
tissues, correlation between PCR and serological results was found in 3 studies (Table 
4)17, 23-28. 
 
Table 4. Correlation between polymerase chain reaction (PCR) and serology (MIF) in 7 studies in 
which arterial tissues were investigated. 
Reference Material No. PCR+
 a 
& MIF+ 
PCR -b 
& MIF- 
PCR+ 
& MIF- 
PCR- 
& MIF+ 
Correlation, 
Kappa 
(p value) 
Kuo et al. 
1993b 
Coronary 
atheromas 29 8 2 5 14 0.2 (0.1) 
Maass et al. 
1998a Coronary arteries 158 34 24 0 100 0.1 (0.005) 
Blasi et al. 
1996 AAA 51 25 9 1 16 0.3 (0.004) 
Maass et al. 
1998b 
Carotid 
endarterectomy & 
restenotic bypass 
70 21 2 0 47 0.03 (0.3) 
Maass et al. 
1997 
Carotid 
endarterectomy 47 7 8 0 32 0.07 (0.2) 
Blasi et al. 
1999 AAA 41 16 14 1 10 0.3 (0.01) 
Jantos et al. 
1999 
Coronary 
atheromas 40 2 16 1 21 0.02 (0.7) 
a + Positive; b - Negative; c AAA; abdominal aortic aneurysms 
 
Large differences in detection prevalence of C. pneumoniae between 
atherosclerotic arterial lesions and non-atherosclerotic arterial controls have been 
reported, 51% (303 of 597) and 4% (5 of 131), respectively5. This is consistent with the 
results of the present study, since C. pneumoniae was more frequently detected in 
atherosclerotic tissues. It has been suggested that C. pneumoniae might be less 
frequently disseminated to non-atherosclerotic tissues or it does not persist for a long 
time in these tissues6. 
In a previous study, we detected M. pneumoniae in one of  39 atherectomy 
specimens and in two of 64 degenerative heart valves4. In the present study, we 
CORRELATION BETWEEN DETECTION METHODS OF C.PNEUMONIAE 
 
 31
simultaneously performed C. pneumoniae- and M. pneumoniae-PCR on atherosclerotic 
and non-atherosclerotic tissues. One specimen was positive in the M. pneumoniae-PCR, 
and 15 specimens were positive in the C. pneumoniae-PCR. These results add a new 
evidence for the specificity of the association between C. pneumoniae and vascular 
disease.   
In conclusion, the results of this study show a good correlation between PCR and 
IHC in the detection of C. pneumoniae in atherosclerotic tissues, and support the 
specificity of the association between C. pneumoniae and atherosclerotic lesions. 
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SUMMARY 
 
The objective of this study was to compare four procedures for Chlamydia pneumoniae-
DNA extraction from vascular tissue. NucliSensTMKit, QIAamp® tissue DNA MiniKit, 
buffer-saturated phenol, and Geneclean II® Kit, were evaluated, based on the yield of 
recovered DNA using PCR to detect Chlamydia pneumoniae in vascular tissue. The 
QIAamp® tissue procedure had the highest detection level (0.004 IFU / sample). All 
methods, except NucliSens (70 minutes), had a short handling time (30-40 minutes). 
Costs varied from 0.5 to 3.2 euro.  
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INTRODUCTION 
 
Chlamydia (C.) pneumoniae has been associated with atherosclerosis. First of all, 
seroepidemiological studies suggested this association1,2. Two recent studies, however, 
have failed to demonstrate any such connection3,4. Subsequently, further evidence has 
been provided by the detection of C. pneumoniae in atherosclerotic tissue by 
polymerase chain reaction (PCR), immunocytochemistry5-7, and also by isolation in 
culture. Whether C. pneumoniae plays a role in the pathogenesis of atherosclerosis is 
still not known. Although serological assays are considered the reference diagnostic 
method for C. pneumoniae infections, PCR is potentially an important tool for further 
studies in this field. C. pneumoniae-PCR is however not yet standardised. Several PCR 
assays have been used to detect C. pneumoniae in vascular tissues. However, a 
considerable variation in the detection rate of C. pneumoniae, ranging from 0% to 100%, 
has been reported by different investigators5-10. This phenomenon can be explained by 
the differences between the populations studied, by sampling error, but also by the 
difference between the PCR techniques applied. The potential for differences in 
performance between PCR techniques is well known. For example, the sensitivity of 
PCR for the detection of Mycobacterium tuberculosis in samples containing low numbers 
of micro-organisms, varied among seven laboratories from 2 – 90%11. A multicenter 
study showed major inter-laboratory differences in the detection rate of C. pneumoniae 
in endarterectomy specimens12. Therefore, it is important to arrive at a more 
standardised procedure including DNA extraction from specimens. In order to detect C. 
pneumoniae by PCR, efficient release of C. pneumoniae-DNA from vascular tissue and 
adequate removal of PCR inhibitors (presence of lipids and calcification) are essential13. 
The purpose of this study is to compare four procedures of C. pneumoniae-DNA 
extraction from vascular tissue. 
 
 
MATERIAL & METHODS 
 
Vascular samples were obtained from 30 patients during cardiac surgery (CABG). 
During this procedure a punch through the aortic wall is routinely taken. This punch was 
stored at 4ºC in 200 µl of lysis buffer (1M Tris pH 7.0, 0.5 mM EDTA, 5M NaCl, 1% SDS, 
20 mg/ml proteinase K) for a maximum of 24 hours. Subsequently, the sample was lysed 
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by adding 20 µl proteinase-K (20mg/ml, Qiagen) and incubating overnight at 56ºC. After 
cell lysis a homogeneous solution was made by pooling all 30 lysates. Seven 900 µl 
portions of the homogenate were inoculated with decreasing concentrations of inclusion-
forming units (IFU) of C. pneumoniae strain TW 183. Portion number eight, containing 
AE buffer (QIAamp, Qiagen, Germany), was used as a negative control.  
Two hundred and five µl of each portion (corresponding to the concentrations of 
the dilution series (ten- and fivefold): 10,000, 1000, 100, 10, and 2, 0.4, 0.08 IFU per 205 
µl; per PCR this is: 500, 50, 5, 0.5, 0.1, 0.02 and 0.004 IFU) was subjected to each of 
four methods of DNA extraction: 
Method I. Using NucliSensTM (Organon Teknika, Boxtel, NL), based on the method of 
Boom et al.14, according to manufacturer’s instructions. This technique is based on 
the mechanism whereby DNA binds to glass particles (silica) in a high 
concentration of chaotropic salt, while contaminants such as proteins, 
carbohydrates, and ions do not. A wash procedure is repeated three times to 
remove all contaminants (with wash buffer, or 70% ethanol or acetone). DNA is 
eluted from the silica by resuspension of the silica complexes in 
NucliSens™elution buffer. 
Method II. Using QIAamp® DNA MiniKit ( Qiagen, Hilden, Germany), according to the 
QIAamp tissue protocol of the manufacturer’s instructions. This method uses a 
QIAamp spin column to which DNA binds in the presence of buffer AL and ethanol. 
Two wash steps, in which AW1 buffer and AW2 buffer succeed each other, are 
performed to remove contaminants. AE buffer is finally used for elution of the DNA 
from the spin column. 
Method III. Using buffer-saturated phenol (Life Technologies, Inc. US California). This 
method is home-made, based on "classical" phenol extraction. In this method 200 
µl of buffer-saturated phenol (pH 7.5 – 7.8) was added to 205 µl of sample in a 1.5-
ml screw-cap plastic tube, vortexed for 1 min and centrifuged for 5 min at 20,000 x 
g. The aqueous supernatant was transferred to another tube which also contained 
200 µl of buffer-saturated phenol. After homogenizing and centrifuging (5 min at 
20,000 x g), the aqueous supernatant was transferred to a 1.5-ml screw-cap 
plastic tube containing 20 µl 3 M NaAc (pH 5,2) and vortexed. 440 µl of ice-cold 
absolute ethanol was added, the mixture homogenized and incubated at -20°C for 
15 min. The sample was centrifuged (15 min, 20,000 x g) to pellet the DNA 
products. The supernatant was removed, and the pellet resuspended in 250 µl of 
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70% ethanol, vortexed and centrifuged for 5 min (20,000 x g). The supernatant 
was removed again, and a quick centrifuge spin was done, so that the remaining 
ethanol could be removed. The pellet was air dried in a half-open tube and 
suspended in 100 µl of AE buffer by vortexing. 
Method IV. Using the Geneclean II® Kit (Qbiogene, Illkirch Cedex, France), according to 
manufacturer’s instructions. Like method I, this method is also based on the 
mechanism that DNA binds to glass particles in a high concentration of chaotropic 
salt. Here the DNA binds to Glassmilk®. The Glassmilk®/DNA pellet is washed 
once with New Wash®.   
All DNA elutions (in 100 µl of AE buffer, Qiagen) were resuspended at 80°C for 5 min, 
which completed the DNA extraction.  
An identical PCR assay was performed on 5 µl of each sample to detect C. pneumoniae-
DNA, irrespective of extraction method. All amplification steps, assay conditions, signals, 
visualisation steps and hybridisation procedures were identical. 
 
Polymerase chain reaction 
Primers CpnA: 5’-TGA CAA CTG TAG AAA TAC AGC-3’ and CpnB: 5’-CGC CTC TCT 
CCT ATA AAT-3’ were used in a PCR based on the 16S rRNA gene sequence as 
described by Gaydos et al.15.  
The PCR reaction mixture contained 30 pmol of each primer, 3 mM MgCl2, 200 
µM dNTPs (dTTP is replaced by dUTP), 2.5 units of AmpliTaq Gold DNA polymerase 
(Perkin Elmer Cetus, Norwalk, Conn.), and 10 x PCR buffer II (Perkin Elmer), and 1.25 
µl of internal control.  
An internal control was added in each reaction to be able to detect inhibition of 
the PCR reaction and prevent false-negative PCR results. The internal control template 
DNA consisted of a PCR product of an unknown fragment of E. coli DNA, that yields a 
150bp-PCR product in combination with primer PINTK (5’- (ACTG x 4)-AC-3’). 
The PCR amplification was performed as follows: after addition of 5 µl of 
template DNA in a final volume of 25 µl PCR reaction mixture, samples were subjected 
to the following PCR program: 10 min at 96ºC, followed by 40 cycles of 30s at 95ºC, 30s 
at 55ºC, and 1 min at 72ºC. A final step of 10 min at 72ºC completed the PCR in a 
thermocycler (9600, Perkin Elmer). A negative PCR mix control and a negative sample 
processing control were included in each PCR run with every 5 samples to detect false-
positive results. 
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 For final product detection, amplification products were examined by agarose gel 
electrophoresis and dot-blot hybridization as follows: eight µl of each PCR product was 
analysed by agarose gel-electrophoresis on 2% agarose gels in TBE buffer containing 
ethidium-bromide. PCR products were visualized on UV transillumination and 
photographed. If the 450 base-pair (bp) Chlamydia-derived band was visible (with or 
without the 150 bp band), the sample was considered positive. If only the 150 bp band of 
the internal control was visible, the sample was considered negative. If no bands were 
visible, the PCR was considered inhibited, and the sample was repurified and retested 
by PCR.  
Dot-blot hybridization: hybridization of 5 µl of the PCR products was performed 
using a 5’-biotinylated C. pneumoniae specific probe, Cpneu-B: 5’-
ACACACGTGCTACAATGGTT-3’. Hybridization signals were visualized using 
streptavidin-peroxidase (Boehringer Mannheim) and ECL detection reagents 
(Amersham). 
 To minimise the risk of contamination, sample preparation, PCR amplification, 
and analysis of the PCR product were performed in separate rooms. 
Analysis. comparison of the four procedures was done using gel electrophoresis 
and dot-blot hybridization. Each procedure was also compared for overall-time 
consumption and hands-on-time per sample. Hands-on-time was defined as time 
needed by the technician working with this procedure, overall-time as the total of time 
including centrifuging, incubation, etc. Finally, the average costs per sample were 
estimated in euro's, calculated by the price of the commercial kit and material (e.g. 
ethanol), excluding the use of materials such as plastic tubes, divided by the number of 
samples. 
 
RESULTS 
 
Figure 1 shows the results of C. pneumoniae detection for each method. The detection 
levels ranged from 0.004 IFU per sample for QIAamp® to 0.1 IFU per sample for Phenol-
extraction and NucliSens, and 0.5 IFU per sample for Geneclean II (table 1). 
Time consumption was in favour of Geneclean II, with a hands-on-time of thirty 
minutes, and an overall-time of sixty minutes and therefore the least labour-intensive 
(table 1). Costs per sample of various methods shows that buffer-saturated phenol was 
the cheapest method with an average of 0.5 euro per sample (table 1).
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DISCUSSION 
 
In this study, we compared four different DNA extraction methods. To create realistic 
study material, a homogenate solution was prepared from aorta tissue samples 
inoculated with IFU’s from C. pneumoniae. The QIAamp® DNA MiniKit extraction method 
detected the lowest amount of IFU’s by far. Also it is a rapid and easy-to-perform 
procedure. The associated costs are a disadvantage. 
Several factors influence the ability of PCR to detect C. pneumoniae, including 
sample preparation, DNA extraction, amplification assays, and visualisation procedures. 
Standardisation of these factors was therefore approached in the present study. 
 Because C. pneumoniae is an intracellular pathogen, vascular tissue was treated 
with proteinase-K to produce tissue cell lysis and release C. pneumoniae-DNA, if 
present. The aorta samples used in the present study were macroscopically non-
atherosclerotic, and the expected positivity rate was low16. Since the amount of C. 
         NucliSens                QIAamp         
         Phenol                  Genclean II       
Figure 1. Agarose gel electrophoresis of 
PCR products (Chlamydia pneumoniae) 
using four DNA extraction methods. 
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pneumoniae in the study materials was unknown, a homogeneous pool of all 30 lysates 
was made and inoculated with decreasing concentrations of IFU's to be able to compare 
DNA extraction methods. It should be mentioned that the concentration of C. 
pneumoniae in the dilution series is very similar, though it is impossible to achieve 
identical concentrations. Moreover, it is not known whether the ability of the four 
procedures to extract C. pneumoniae-DNA from spiked materials is the same as their 
ability to extract DNA from patient materials12.  
 A multicenter study12 demonstrated that the sensitivity of a PCR assay does not 
necessarily correspond with the ability to detect C. pneumoniae in patient material 
without a logical explanation. In the present study we performed one PCR assay, and 
because there is no reference assay available, one should view the results of the 
present study in the light of the lack of a reference PCR assay.     
Taking the limitations of the present study into consideration, we can conclude 
that QIAamp is a useful and sensitive DNA-extraction method, but further effort to 
optimise and standardise DNA-extraction methods is needed.  
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SUMMARY 
 
Small clinical trials have indicated that antibiotic treatment of Chlamydia (C.) 
pneumoniae has clinical beneficial effects in patients with coronary artery disease  
(CAD). It has not been demonstrated if antibiotic treatment eradicates C. pneumoniae 
from vascular tissue. The aim of this study was to assess the effect of clarithromycin on 
the presence of C. pneumoniae in vascular tissue of patients with CAD. 
Patients with CAD, waiting for coronary artery bypass graft surgery were enrolled into a 
randomised, double-blind, placebo-controlled trial. Patients were randomly assigned to 
receive clarithromycin 500 mg or placebo once daily, from the day of inclusion till 
surgery. During surgery vascular specimens were obtained. The presence of C. 
pneumoniae in vascular specimens was examined by immunohistochemistry (IHC) and 
two polymerase chain reaction (PCR) assays. Baseline Chlamydia IgG titers and titers 8 
weeks after surgery were determined using an enzyme immunoassay. 
A total of 76 patients were included and 180 vascular specimens were obtained, 80 
specimens from the clarithromycin group and 100 specimens from the placebo group. 35 
patients received clarithromycin (mean= 27 days, SD =12.2) and 41 placebo (mean=27 
days, SD=13.9). IHC detected C. pneumoniae major outer membrane protein antigen in 
73.8% of specimens in the clarithromycin group vs. 77.0% in the placebo group (p=ns). 
Chlamydia lipopolysaccharide antigen was found in one placebo specimen. C. 
pneumoniae DNA was not detected by PCR in any specimen. Baseline Chlamydia IgG 
titers were equally distributed in both groups and were not significantly different after 
treatment. 
Clarithromycin treatment of patients with CAD has neither an effect on the presence of 
C. pneumoniae in vascular tissue nor on Chlamydia IgG titers. 
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INTRODUCTION 
 
Many risk factors for atherosclerosis are well defined. However, atherogenesis is not 
fully understood and infectious pathogens, particularly Chlamydia (C.) pneumoniae, 
have been considered as potential risk factors for atherosclerosis1. It has been supposed 
that, during respiratory tract infection, C. pneumoniae reaches vascular tissue via 
infected leukocytes. In vascular tissue, C. pneumoniae can infect atheroma-associated 
cells and induce inflammatory cytokines production and smooth muscle cells 
proliferation2. C. pneumoniae may also cause endothelial dysfunction and promote the 
secretion of matrix-degrading metalloproteinases that destabilize the atherosclerotic 
plaque2,3. Chlamydial lipopolysaccharide (LPS) and chlamydial heat shock protein 60 kd 
may contribute to atherogenesis by promoting foam cells formation, lipoprotein oxidation 
and proinflammatory activation2. 
 Some seroepidemiologic studies have found an association between C. 
pneumoniae and coronary artery disease (CAD). Prospective serologic studies, 
however, failed to demonstrate any association4. Further indications that C. pneumoniae 
might play a role in atherogenesis came from studies that identified C. pneumoniae in 
vascular tissue by polymerase chain reaction (PCR), immunohistochemical staining 
(IHC), electron microscopy, and culture1. However, the results of these studies are 
inconsistent and a huge variation in the detection rate has been reported1,5. 
 The results of pilot clinical trials that showed beneficial effects from antibiotic 
treatment encouraged many groups to further investigate the effect of antibiotic 
treatment on secondary prevention of cardiovascular events6-8. These studies are based 
on the hypothesis that antibiotic treatment of C. pneumoniae in CAD patients will 
stabilize atheromas and decrease cardiovascular events. However, it has not been 
studied whether antibiotic treatment eradicates C. pneumoniae from vascular tissue of 
CAD patients. We initiated in 1999 a placebo-controlled, double-blind, randomised 
clinical trial to investigate the effect of clarithromycin treatment on the presence of C. 
pneumoniae in vascular tissue, and on circulating Chlamydia IgG antibodies in patients 
with CAD. Two PCR assays and IHC staining were used to assess the eradication of C. 
pneumoniae from vascular tissue. 
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PATIENTS AND METHODS 
 
Study population 
Between July 1999 and July 2001, patients with documented CAD and scheduled for 
coronary artery bypass graft (CABG) surgery were invited to participate in the study. 
Inclusion was carried out during attendance at the pre-operative outpatient clinic at the 
department of thoracic surgery of the Amphia Hospital. Exclusion criteria included: (I) 
concomitant administration of terfenadine, rifabutin or cisapride; (II) Antibiotic therapy 
with a macrolide, tetracycline, or quinolone within three months prior to inclusion or 
during the study period; (III) Renal failure (serum creatinine rates above 150 µmol/l); (IV) 
elevated liver function (alanine-aminotransferase > 55 U/l, aspartate-aminotransferase > 
45 U/l, total bilirubin > 27 µmol/l, or alkaline phosphatase  > 180 U/l); (V) female patients 
capable of child-bearing but not taking adequate birth control precautions. 
 After giving informed consent, patients were randomised in a double-blind, 
placebo controlled trial. Patients received, from the day of inclusion till the day of 
surgery, a daily dose of clarithromycin 500 mg slow release (SR) or a placebo tablet 
(Clarithromycin SR and matching placebo tablets were obtained from Abbott 
laboratories, Abbott Laboratories Ltd, Queenborough, Kent, England ME11 5EL).  
 An independent pharmacist dispensed either clarithromycin or placebo tablets 
according to a computer-generated randomisation table, which stratified in groups of 10. 
The researcher responsible for seeing the patients allocated the next available number 
on entry into the trial, and provided the patient the corresponding tablets. The code was 
revealed to the researcher once recruitment, data collection, and laboratory analysis 
were complete. The local Medical Ethics Committee approved the study. 
 
Clinical specimens 
During CABG surgery specimens were obtained from coronary atheromas, obstructed 
old coronary grafts, mammary artery, saphenal vein, when possible. All specimens were 
divided into two portions, one for IHC and one for PCR. IHC samples were routinely fixed 
in 10% buffered formalin until further research. PCR samples were transported at 4ºC in 
200 µl of lysis buffer (1M Tris pH 7.0, 0.5 mM EDTA, 5M NaCl, 1% SDS, 20 mg/ml 
proteinase K), and processed within 24 hours. 
EFFECT OF CLARITHROMYCIN ON CHLAMYDIA PNEUMONIAE IN VASCULAR TISSUE 
 49
From each patient 10 ml blood was obtained on the day of inclusion and 8 weeks after 
surgery. Blood was stored at 4ºC immediately after collection, and centrifuged within two 
hours. Serum was then stored at -20ºC pending further testing.  
 
Laboratory methods 
Serology. Chlamydia IgG antibody titers were determined by a recombinant enzyme 
immunoassay (rELISA, Medac GmbH, Hamburg, Germany) according to the 
manufacturer’s instructions. This rELISA uses a recombinant Chlamydia-specific LPS 
fragment as antigen. IgG titer of > 1:100 was considered positive.   
Immunohistochemistry. Cross-sections of each paraffin wax embedded vascular 
specimen were stained with hematoxilin-eosin stain. In each cross-section, the lumen 
area, the circumference of the internal elastic lamina and the area encompassed by it, 
were evaluated. Antigens were detected in 4 µm sections by IHC as described by Meijer 
et al.9. In the IHC, two monoclonal antibodies were used. The species specific 
monoclonal antibody RR-402 against C. pneumoniae major outer membrane protein 
(MOMP) (Washington Research Foundation, Seattle, Washington, USA)10, and the 
Chlamydia genus specific anti-LPS monoclonal antibody 16.3B6 (produced by the 
National Institute of Public Health and the Environment, Bilthoven, The Netherlands). 
HEp2 cells (CCL23; American Type Culture Collection) infected with C. pneumoniae 
strain TW-183 were used as positive control, and mock-infected HEp2 cells were used 
as negative control. 
 The specimens were evaluated microscopically by one experienced technician. 
Specimens were considered positive for C. pneumoniae antigen when a clear dot-like-
cell associated staining was observed5.  
 
Polymerase chain reaction 
Specimens processing. Within 24 hours after surgery, DNA was extracted from 
clinical specimens by the QIAamp DNA mini kit (Qiagen Inc., Valencia, Calif.) according 
to the manufacturer’s instructions. A control was included with every four clinical 
specimens in the extraction procedure. 
Real-time PCR. A real-time PCR assay specific for C. pneumoniae and designed 
to the VD4 variable domain of the ompA gene was performed. Oligonucleotide primers 
included VD4 forward primer (5'-TCC GCA TTG CTC AGC C-3'), VD4 reversed primer 
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(5'-AAA CAA TTT GCA TGA AGT CTG AGA A-3'), and a VD4 probe (5'-FAM-TAA ACT 
TAA CTG CAT GGA ACC CTT CTT TAC TAG G-TAMRA)11. 
 To be able to monitor possible inhibition of PCR in the clinical specimens a 
universal internal control was used. This internal control sample consisted of a whole-
virus preparation of phocid herpesvirus (PhHV-1),12 which was added to the original 
clinical sample at a final concentration of approximately 5,000 to 10,000 DNA copies per 
ml. Primers PhHV-F1 (5'-GGG CGA ATC ACA GAT TGA ATC-3'), PhHV-R1 (5'-GCG 
GTT CCA AAC GTA CCA A-3') and probe (5'-VIC-TTT TTT ATG TGT CCG CCA CCA 
TCT GGA TC-TAMRA-3') were used to amplify PhHV1, which in uninhibited samples 
had a cycle threshold value of approximately 30. Amplification was carried out with both 
C. pneumoniae and PhHV1 specific primers and probes in a multiplex PCR. 
 Reactions were prepared with 96-well MicroAmp optical plate (Applied 
Biosystems) by addition of 5 µl of extracted DNA to 45 µl of PCR mixture containing 1x 
TaqMan universal PCR master mix (Applied Biosystems), 600nM VD4 forward primer, 
300nM VD4 reversed primer, and 150 nM FAM fluorescent C. pneumoniae specific 
probe, 5 µl PhHV1 (whole-virus), 400 nM PhHV-F1 forward primer, 400 nM PhHV-R1 
reversed primer, and 150 nM VIC-labeled PhHV-1 specific probe. The 96-well plate was 
centrifuged for 1 min at 1,000 xg at room temperature in a swing-out rotor to remove 
small air bubbles in the reaction vessels. Amplification and detection were performed 
with an ABI Prism 7900HT sequence detection system (Applied Biosystems) by using the 
manufacturer's standard protocols. The PCR cycling program consisted of 2 min at 
50°C, 10 min at 95°C, and 50 cycles of 15s at 95°C and 1 min at 60°C. Each run 
contained: (I) negative controls (one for every four extracted DNA samples); (II) positive 
control series containing a known amount of inclusion forming units (IFU) of C. 
pneumoniae (5, 2, and 1 IFU); (III) a negative mix control. A specimen was considered 
positive for C. pneumoniae if the fluorescence was above the threshold limit. Specimens 
were considered negative for C. pneumoniae if the internal control was positive with a 
cycle threshold value of < 35. 
Industry-developed research-use-only LCx C. pneumoniae PCR (RUO-PCR).      
The presence of C. pneumoniae DNA in specimens was also examined by an Industry-
developed LCx C. pneumoniae RUO-PCR (Diagnostics Division, Abbott Laboratories, 
Abbott Park, Chicago, Illinois, USA). The RUO-PCR assay was performed at Abbott 
Laboratories by Abbott personnel as described earlier13. Briefly, an activation mixture 
was prepared by mixing equal volumes of LCx Activation Reagent II and LCx C. 
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pneumoniae Oligo Mix. 40 µl of the freshly prepared activation mixture and 30 µl of the 
purified DNA samples were subsequently added to the appropriate LCx amplification 
vial. The total reaction volume was 200 µl. Amplification was carried out with a 480 
thermocycler (Perkin-Elmer, Norwalk, Conn.) under the following conditions: 97°C for 2 
min; 40 cycles of 97°C for 30 s, 59°C for 30 s, and 72°C for 30 s; and finally, 1 cycle of 
97°C for 5 min and 12°C for 5 min. PCR products were detected with the LCx Analyzer. 
Samples yielding a rate over 100 cps per second were considered C. pneumoniae 
positive. This cutoff was determined by testing titrated C. pneumoniae isolates and 
uninfected HEp-2 cell DNA multiple times13. 
 Specimens were coded and all detection experiments were performed blind. The 
code was revealed when the study was completed. 
 
Statistical analysis 
All baseline characteristics were analyzed using a χ2-test or a Student’s t test when 
appropriate. A value of P<0.05 was considered statistically significant. The SPSS 11.0 
statistical software package was used for all calculations. 
 
 
 
 
Figure 1. Trial Profile. 
 
80 total eligible patients 
80 patients randomized 
3 excluded from analysis 
because of concomitant 
use of other antibiotics 
during study period
1 excluded from analysis 
because of concomitant use 
of other antibiotics during 
study period 
35 analyzed 41 analyzed
42 placebo 38 clarithromycin 
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RESULTS 
 
Figure 1 shows that a total of 80 patients with CAD, waiting for CABG surgery, were 
enrolled in the study. Four patients who during the study period concomitantly used 
other antibiotics were excluded from this treatment analysis due to possible additive 
effects. Thirty-five patients were randomly assigned to receive clarithromycin and 41 to 
receive placebo. Table 1 shows that the baseline patient characteristics are well 
balanced between the two treatment groups. The mean number of treatment-days, for 
both groups, was 27 as indicated by the number of tablets used.  
 
Tabel 1. Baseline patient characteristicsa. 
Characteristics Clarithromycin, 
n = 35 
Placebo, 
n = 41 
   Male 32 (91.4) 35 (85.3) 
   Age, mean 65 (8.6) 65 (9.3) 
   Weight, mean 84 (19.4) 81 (12.1) 
   Length, mean 170 (20.2) 174 (9.9) 
   NYHA-score, mean 3 (0.9) 3 (0.7) 
   Treatment-days, mean 27 (12.2) 27 (13.9) 
   Current smoker 5 (14.3) 4 (9.8) 
   Smoker in past 27 (77.1) 31 (75.6) 
Medical history   
   COPD 6 (17.1) 3 (7.3) 
2 (5.7) 1 (2.4)    Diabetes Mellitus   - Type I 
                                 - Type II 4 (11.4) 8 (19.5) 
   Hypercholesterolaemia 20 (57.1) 27 (65.9) 
   Malignancy 3 (8.6) 1 (2.4) 
   CVA or TIA 2 (5.7) 6 (14.6) 
   Pectoral angina 33 (94.3) 40 (97.6) 
   Myocardal infarction 20 (57.1) 23 (56.1) 
   Valvular insufficience 3 (8.6) 1 (2.4) 
   Hypertension 18 (51.4) 25 (61.0) 
   Earlier vascular surgery 10 (28.6) 15 (36.6) 
Family medical history   
   Cardiovascular disease 29 (82.9) 31 (75.6) 
   Diabetes mellitus 7 (20.0) 6 (14.6) 
Medication   
   Statins 21 (60.0) 27 (65.9) 
   Anti-hypertensive drugs 35 (100) 41 (100) 
Values are means (SD) or numbers (%); 
a Baseline patient characteristics are not significantly different between the treatment groups. 
 
During CABG surgery, 180 vascular specimens were obtained, including coronary 
atheromas (n=31), obstructed old CABG specimens (n=12), mammary artery specimens 
(n=66), and saphenal vein specimens (n=71). All atheromas and obstructed old CABG 
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specimens showed histological signs of inflammation and advanced atherosclerosis 
(thickened intima, plaques with thrombus, lymfocytes, foamcells, surface defects). The 
other specimens showed normal to slightly thickened vascular walls. 
 The results of IHC are presented in table 2. C. pneumoniae MOMP antigen was 
found in the majority of specimens of both study groups. Chlamydia LPS antigen was 
found only once, in an atheroma from the placebo group. There was no significant 
difference in the presence of antigens between the two groups. The real-time PCR and 
the RUO-PCR failed to detect C. pneumoniae DNA in the 180 vascular specimens. 
 
 
Table 2. Results of immunohistochemical staining of the vascular specimens obtained from the 
study patientsa. 
 Clarithromycin Placebo p valueb 
 Positive specimens/ 
specimens tested, (%) 
Positive specimens/ 
specimens tested, (%) 
 
Coronary atheroma    
                  MOMPc 10/14 (71.4) 10/17 (58.8) 0.47 
                  LPSd 0/14 (0) 1/17 (5.9) 0.36 
Old coronary grafte    
                  MOMP 6/6 (100) 5/6 (83.3) 0.30 
                  LPS 0/6 (0) 0/6 (0) 1.00 
Mammary artery    
                  MOMP 22/28 (78.6) 30/38 (78.9) 0.97 
                  LPS 0/28 (0) 0/38 (0) 1.00 
Saphenal vein    
                  MOMP 21/32 (65.6) 32/39 (82.1) 0.11 
                  LPS 0/32 (0) 0/39 (0) 1.00 
Total     
                  MOMP 59/80 (73.7) 77/100 (77.0) 0.69 
                  LPS 0/80 (0) 1/100 (1.0) 1.00 
Values are numbers (%); 
a more than one specimen was obtained from some patients; 
b a p-value of < 0·05 is considered statistically significant; 
c MOMP, C. pneumoniae major outer membrane protein antigen; 
d LPS, Chlamydia lipopolysaccharide antigen; 
e Obstructed old bypass graft from earlier CABG procedure. 
 
Chlamydia IgG antibody titers were measured on inclusion (baseline serology) and 8 
weeks after completion of treatment. Baseline serology was positive in 81.6% and 73.8% 
of the patients in the clarithromycin group and the placebo group, respectively. The 
corresponding percentages 8 weeks after treatment were 78.9% and 66.7%, 
respectively. Clarithromycin had no significant effect on Chlamydia IgG antibody titers. In 
both treatment groups, Chlamydia IgG antibody titers after treatment were not 
significantly different to the baseline titers. 
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DISCUSSION 
 
Macrolide antibiotics, including clarithromycin, are active against C. pneumoniae. The 
hypothesis that C. pneumoniae is a risk factor for atherosclerosis has lead to clinical 
trials of macrolide treatment in patients with CAD8. Human placebo-controlled trials have 
been performed to investigate the clinical effects of antibiotics in patients with vascular 
disease, but they have not demonstrated whether antibiotics could achieve 
microbiological cure in vascular tissue. 
 Our study was designed to examine whether clarithromycin treatment can 
eradicate C. pneumoniae from vascular tissue of patients with CAD. We assessed the 
effect of clarithromycin treatment on the presence of C. pneumoniae in vascular tissue 
by IHC and two PCR assays. Also, we evaluated the effect of clarithromycin on 
Chlamydia IgG titers. 
 In the present study, vascular specimens were tested by an automated real-time 
PCR, which combines amplification, hybridization and quantitative product detection. 
Moreover, the specimens were tested by an industry-developed RUO-PCR. However, 
these two methods failed to detect C. pneumoniae DNA in any specimen. This indicates 
that there is no evidence of acute C. pneumoniae infection in vascular tissue of CAD 
patients. Other possible explanations for the negative results of the PCR assays could 
be the low DNA concentration in the test samples and the patchy distribution of C. 
pneumoniae DNA in vascular tissue14. An important difference between our study and 
the study of Melissano et al.15. is the high detection rate of C. pneumoniae DNA in their 
study. Melissano et al. evaluated the effect of roxithromycin on C. pneumoniae in carotid 
atheromas. The authors concluded that roxithromycin treatment was effective in 
eradicating C. pneumoniae from carotid atheromas since C. pneumoniae DNA was 
detected in 31% (5/16) of the atheromas in the roxithromycin group and in 75% (12/16) 
of the atheromas in the control group. However, they used one unstandardised 
conventional semi-nested PCR assay to detect C. pneumoniae DNA. Conventional PCR 
assays are unstandardised and known to produce conflicting results16,17. Also, taking the 
limitations of the design of the study of Melissano et al. (open and not placebo-
controlled) into account, the reliability of their results may be questioned. Efforts have 
been recently focussed on the establishment of quantitative real-time PCR technology. 
Although the real-time PCR and the RUO-PCR are not standardised, the first reports on 
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the evaluation of these tests suggest that they are sensitive, specific and 
reproducible13,18. 
 Another finding of our study is the high prevalence of C. pneumoniae MOMP 
antigen in vascular specimens. High detection rate of C. pneumoniae antigens has been 
reported by others1. However, protocols of performance and interpretation of IHC are not 
standardized 5. IHC requires a subjective reading and its interpretation remains difficult 
because of background staining and nonspecific staining with antigenic components in 
vascular specimens, such as inflammatory cells and tissue components19-21. It is also 
possible that components of Chlamydia-like microorganisms described recently can 
cause cross-reactivity to the monoclonal antibodies used in IHC staining9. 
 IHC detected C. pneumoniae MOMP antigen in 73.8% of specimens in the 
clarithromycin group and in 77.0% of the specimens in the placebo group (p=ns). 
Chlamydia LPS antigen was detected by IHC in only one specimen from the placebo 
group. These results are consistent with the findings of other investigators. The 
abundance of MOMP antigen and low detection rate of LPS antigen, in absence of C. 
pneumoniae DNA in vascular specimens has been reported before9,22. 
 The conflicting results concerning the high detection rate of C. pneumoniae 
MOMP antigen and the low detection rate of C. pneumoniae DNA might be partly 
explained by the biology of Chlamydiae23. Alternation of activity and latency 
characterizes infections with Chlamydiae. In advanced Chlamydiae infections, the 
pathogen is no longer present, whereas its antigens can persist for a long time. The 
persisting antigens may cause a cascade of events leading to fibrosis and scaring23. 
 In the present study, we could not demonstrate any effect of clarithromycin on the 
presence of C. pneumoniae MOMP antigen in vascular tissue. Similar finding has been 
demonstrated in animal models. Antibiotic treatment with azithromycin was not found 
associated with elimination of chlamydial antigen from vascular specimens of rabbits 
infected with C. pneumoniae24. Also, in a mice model, azithromycin treatment did not 
affect the presence of C. pneumoniae in the aorta, lung, or spleen25. 
 Clarithromycin treatment had no effect on Chlamydia IgG antibody titers, and we 
found no significant difference between baseline titers and the titers measured 8 weeks 
after treatment. Circulating Chlamydia antibody titers have been used as a marker of 
response to antibiotic treatment6. Gupta et al.6 reported a significant effect of 
azithromycin on Chlamydia IgG antibody titers. However, our study supports the results 
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of many other clinical trials that have shown that antibiotic therapy does not influence 
Chlamydia antibody titers in patients with vascular disease26-30. 
 This is the first placebo-controlled, double-blind, randomised clinical trial that 
assessed the effect of antibiotic treatment on the presence of C. pneumoniae in vascular 
specimens. A major finding in this study was, that in vascular tissues of patients with 
advanced CAD, no viable C. pneumoniae were present, but antigen debris of C. 
pneumoniae. In the light of these findings, it can be questioned if one can demonstrate 
the effect of antibiotics in patients with advanced atherosclerosis, since viable C. 
pneumoniae is no longer present in vascular tissue. This may explain the results of many 
clinical trials that failed to demonstrate any beneficial effect of antibiotic treatment in 
patients with vascular disease26-32. 
 In conclusion, with use of different detection methods, no evidence could be 
found for the presence of viable C. pneumoniae in vascular tissue of CAD patients. 
Clarithromycin treatment of CAD patients had neither an effect on the presence of C. 
pneumoniae antigens in vascular tissue nor an effect on circulating Chlamydia IgG 
antibody titers. Antibiotic treatment of CAD patients is not indicated and it may not be 
beneficial, since C. pneumoniae infection in these patients is probably not acute and 
viable pathogens are no longer present in their vascular tissue. Future studies should be 
focused on the effects of antibiotic treatment in patients within early stages of 
atherosclerosis. 
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SUMMARY 
 
Atherosclerosis can to a certain extent be regarded as an inflammatory disease. Also, 
inflammatory markers may provide information about the cardiovascular risk. Whether 
macrolide antibiotics, especially clarithromycin, have an anti-inflammatory effect in 
patients with atherosclerosis is not exactly known. 
To study this phenomenon a placebo controlled, randomized, double blind study was 
performed. 231 patients with documented coronary artery disease received a daily dose 
of clarithromycin 500 mg slow release or placebo until the day of surgery. Inflammatory 
markers (C-reactive protein [CRP], interleukin [IL]-2R, IL-6, IL-8, and tumour necrosis 
factor (TNF)-α) were assessed during the pre-operative outpatient visit, on the day of 
surgery, and 8 weeks after surgery. Also changes in the levels of inflammatory markers 
between visits were calculated as delta. 
Baseline patient characteristics were balanced between the two treatment groups: 
average age was 66 years (SD=9.0), 79% of the patients were male, the average 
number of used tablets was 16 (SD=9.3). The inflammatory markers of the groups as 
well as the delta's were not significantly changed. 
Treatment with clarithromycin did not influence the inflammatory markers in patients with 
atherosclerosis.  
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INTRODUCTION 
 
Despite the use of pharmaceutical therapy against known risk factors and changes in 
lifestyle and behaviour, cardiovascular disease remains a leading cause of death 
worldwide1. Apart from well-known risk factors such as elevated and modified low-
density protein (LDL) cholesterol, free radicals (caused by smoking), hypertension, 
diabetes mellitus, genetic alterations, and hyperhomocysteinaemia, infections caused by 
various microorganisms are nowadays also considered potential causes of 
atherosclerosis. For example cytomegalovirus, Helicobacter pylori and Chlamydia 
pneumoniae have been linked to the pathogenesis of atherosclerosis2. In addition, 
atherosclerosis can be regarded as an inflammatory disease3. 
All these risk factors can cause endothelial injury and dysfunction, which in many 
studies is considered the first step in the pathogenesis of atherosclerosis. It forms the 
basis of the so-called response-to-injury hypothesis4. This response to endothelial injury 
is mediated at every stage of atherosclerosis by monocyte-derived macrophages and 
specific subtypes of T lymphocytes3,4. 
 Elevated levels of C-reactive protein (CRP), tumour necrosis factor (TNF)-α or 
interleukine (IL)-6 are all associated with an increased risk of  future myocardial 
infarction5-8. Patients with an elevated CRP level (> 2.0 mg/L) are at risk of recurrent 
angina pectoris and acute myocardial infarction (AMI). Conversely, in patients with 
unstable angina pectoris the CRP level is elevated9. Researchers have now suggested 
that inflammatory markers such as CRP may provide information about the 
cardiovascular risk6. 
 Inflammatory markers such as IL-2R, IL-6, IL-8, TNF-α, and CRP can provide 
information about the mechanism of the inflammatory reaction associated with 
atherosclerosis. IL-2R, IL-6, IL-8, and TNF-α derive from activated monocytes, 
macrophages, T-cells or endothelial cells. These inflammatory markers stimulate 
fibroblasts and smooth muscle cells to proliferate. They may also induce free radical 
generation by neutrophils, and this may facilitate oxidation of low-density protein 
cholesterol and attract monocytes and other inflammatory cells to the area of endothelial 
damage3,10. Cytokines promote the production of endogenous tissue plasminogen 
activator and plasminogen activator inhibitor 1, which stimulate thrombus formation11. 
  There is much speculation about the anti-inflammatory potential of macrolides, 
independent of their well-established role in the chemotherapy of infectious diseases. 
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Macrolides have potentially relevant in-vitro, ex-vivo and in-vivo immunomodulatory 
effects12. To investigate the effect of clarithromycin on inflammatory markers in patients 
prior to coronary artery surgery, we performed a prospective, double-blind, randomized, 
placebo controlled study. 
 
 
MATERIALS AND METHODS  
 
Between July 1999 and July 2001, patients with documented coronary artery disease 
were enrolled in the study. All these patients were scheduled for coronary artery bypass 
graft surgery. Patients were evaluated for inclusion in the study during a visit to the 
preoperative outpatient clinic at the department of thoracic surgery of the Amphia 
Hospital. Exclusion criteria included the following: concomitant administration of 
terfenadine (Triludan), rifabutin (Mycobutin), cisapride (Propulsid), or antipyrine; 
antibiotic therapy with a macrolide, tetracycline, or quinolone within 3 months prior to 
inclusion in the study or during the study period; the presence of renal failure (serum 
creatinine concentrations above 150 µmol/liter), elevated liver function (alanine 
aminotransferase levels of >55 U/liter, aspartate aminotransferase levels of >45 U/liter, 
total bilirubin levels of >27 µmol/liter, alkaline phosphatase levels of >180 U/liter); and for 
female patients capable of childbearing, not taking adequate birth control precautions. 
After the patients gave their informed consent, they were randomized in a double-blind, 
placebo-controlled study. From that point on, they began receiving the study medication 
until the day of surgery. The study medication consisted of either a daily dose of 500 mg 
of slow-release clarithromycin (clarithromycin SR) or a matching placebo tablet (both 
from Abbott laboratories, Ltd., Queenborough, Kent, England). Clarithromycin SR is well 
absorbed following oral administration and well distributed in body fluids and tissues, 
where it achieves high and persistent concentrations (half-life in tissue, 5.3 h). 
From each patient, 10 ml of blood (extracted with EDTA) was obtained at the 
following stages: (i) during the initial preoperative outpatient visit, (ii) on the day of 
surgery just before the operation, and (iii) 8 weeks after surgery. Blood samples were 
stored at 4°C immediately after collection and centrifuged within 2 h. Plasma was then 
stored at -70°C pending further testing. This plasma was analyzed with an IMMULITE 
analyzer according to the manufacturer’s instructions (EURO/DPC Ltd., Glyn Rhonwy, 
United Kingdom) for quantitative estimation of soluble IL-2R (units per liter), IL-6 
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(picograms per liter), IL-8 (picograms per liter), TNF-α (picograms per liter), and CRP 
(milligrams per liter). 
The study was approved by the local medical ethics committee. 
 
Statistical analysis. A sample size calculation was made to measure the effect on the 
CRP value based on the results from a previous study13. In this study the placebo group 
had a mean CRP value of 8.7 mg/liter and a standard deviation (SD) of 6.0. For a 
hypothesized reduction of 30% (2.6 mg/liter) of the CRP with a power of 90% and a 
significance level of 0.05, 113 subjects were needed per study group. 
All baseline characteristics were analyzed by using a Χ2 test for the distribution of 
categorical variables and Student’s t test to compare continuous variables. To assess 
the differences in inflammatory marker values between the two treatment groups, a 
comparison was made using Student’s t test or the Mann-Whitney U test, when 
appropriate. Statistical significance was accepted when P was <0.05. 
 
 
RESULTS 
 
A total of 231 patients were enrolled in the study. After randomization, 117 patients 
received 500 mg of clarithromycin SR and 114 received a placebo. Table 1 shows that 
the baseline patient characteristics were well balanced between the two treatment 
groups. The mean numbers of tablets used before surgery were 16 (SD = 9.5) for the 
clarithromycin group and 17 (SD = 9.6) for the placebo group. The mean age was 66 
years (SD = 8.9) in the clarithromycin group versus 64 years (SD = 9.3) in the placebo 
group. Eighty percent of the clarithromycin group was male versus 78.1% in the placebo 
group. No significant differences were found. 
Eight patients who during the study period simultaneously used antibiotics other 
than a macrolide, tetracycline, or quinolone were excluded from this treatment analysis 
due to possible interference from additive anti-inflammatory effects. The baseline levels 
of inflammatory markers for both treatment groups on the day of the preoperative visit 
(visit 1), as well as the values after treatment on the day of surgery (visit 2) and 8 weeks 
after surgery (visit 3), are shown in Table 2. As the data in the table indicate, there were 
no significant differences in the levels of inflammatory markers between the two groups 
at visit 1, 2, or 3 (Table 2). Changes in the levels of inflammatory markers between visits 
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were also calculated. There were no significant differences in these changes between 
the treatment groups. 
 
 
Table 1. Patient characteristics. 
 Value for group  
Clarithromycin Placebo 
Characteristica (n=113) (n=110) p-value 
    
Age, yr 66 (9.0) 64 (9.4) NSb 
Weight, kg 82 (12.4) 80 (13.4) NS 
Height, cm 172 (8.7) 172 (9.1) NS 
NYHA 2.8 (0.8) 2.8 (0.8) NS 
Pre-operative period (days) 17.7 (10.4) 20.4 (15.8) NS 
Number of tablets used 16 (9.3) 17 (9.6) NS 
Medical history    
    
Male 92 (81.4) 85 (77.3) NS 
Smoker 24 (21.2) 24 (21.8) NS 
COPD 11 (9.7) 12 (10.9) NS 
Diabetes mellitis    
 IDDM 8 (7.1) 8 (7.3) NS 
 NIDDM 13 (11.5) 8 (7.3) NS 
Dyslipidemia 66 (58.4) 70 (63.6) NS 
Malignancy 8 (7.1) 3 (2.7) NS 
Severe underlying disease 6 (5.3) 5 (4.5) NS 
CVA 10 (8.8) 7 (6.4) NS 
Angina pectoris 108 (95.6) 110 (100) NS 
Myocardial infarction 54 (47.8) 49 (44.5) NS 
Heart valve insufficiency 4 (3.5) 3 (2.7) NS 
Hypertension 54 (47.8) 56 (50.9) NS 
Earlier vascular surgery 21 (18.6) 18 (16.4) NS 
Family history    
Heart disease 86 (76.1) 83 (75.5) NS 
Diabetes mellitus  20 (17.7) 17 (15.5) NS 
Medication    
Anti cholesterol 66 (58.4) 69 (62.7) NS 
Anti hypertensives 113 (100) 109 (99.1) NS 
Immunosuppressives 0 (0) 3 (2.7) NS 
a NYHA, stage of heart failure according to the New York Heart Association classification; COPD, chronic 
obstructive pulmonary disease; IDDM, insulin dependent diabetes mellitus; NIDDM, non-insulin dependent 
diabetes mellitus; CVA, cerebrovascular accident. Values for medical and family histories and medication 
are given as number (percent) of patients. Other values (for the first six characteristics) are given as means 
(SDs). 
b NS, not significant. 
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Table 2. inflammatory markers of visit 1, 2 and 3. 
Marker conc b Marker and 
visit no. Treatment group (n) 
a
Mean Std.dev. 
p-value 
CRP     
1 Clarithromycin (113) 4.3 5.9 
 Placebo (108) 3.1 2.9 
0.29c 
2 Clarithromycin (113) 2.8 3.2 
 Placebo (107) 3.2 7.2 
0.61 
3 Clarithromycin (109) 9.7 20.7 
 Placebo (108) 5.8 8.2 
0.15c 
TNF-α     
1 Clarithromycin (113) 90.8 237.3 
 Placebo (108) 130.1 272.9 
0.25 
2 Clarithromycin (113) 263.5 327.6 
 Placebo (107) 313.5 327.6 
0.29 
3 Clarithromycin (109) 157.1 305.6 
 Placebo (106) 154.5 308.3 
0.95 
IL2R     
1 Clarithromycin (113) 547.6 717.6 
 Placebo (109) 476.9 200.8 
0.20c 
2 Clarithromycin (112) 418.6 683.0 
 Placebo (107) 351.7 220.8 
0.33 
3 Clarithromycin (108) 601.0 672.6 
 Placebo (107) 533.2 236.9 
0.33 
IL-6     
1 Clarithromycin (112) 30.7 149.3 
 Placebo (109) 33.1 158.9 
0.91 
2 Clarithromycin (112) 24.7 133.5 
 Placebo (104) 46.3 193.8 
0.34 
3 Clarithromycin (107) 15.6 96.1 
 Placebo (106) 40.2 176.2 
0.93c 
IL-8     
1 Clarithromycin (113) 25.4 116.8 
 Placebo (109) 6.8 12.8 
0.67c 
2 Clarithromycin (113) 20.5 92.2 
 Placebo (107) 7.3 16.6 
0.47c 
3 Clarithromycin (108) 14.2 66.3 
 Placebo (107) 8.8 21.5 
0.42 
a n, number of study patients out of a total of 223. 
b Concentrations are given in milligrams per liter (CRP), picograms per liter 
(TNF-α, IL-6, and IL-8), and units per liter (IL-2R). 
c Determined by the Mann-Whitney test. 
 
 
DISCUSSION 
 
Treatment with a daily dose of 500 mg of clarithromycin SR in patients with coronary 
artery disease prior to cardiac surgery did not significantly alter the inflammatory markers 
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directly after treatment on the day of surgery or 8 weeks after surgery. Clarithromycin 
can therefore be considered to have no or little anti-inflammatory potential. 
The hypothesis that atherosclerosis has an infectious etiology has promoted 
studies of the effect of antibiotics, especially macrolides. The activity against C. 
pneumoniae and the general anti-inflammatory effect on the outcome in patients with 
cardiovascular disease were studied retrospectively as well as prospectively. For 
example, Østergaard et al. in a retrospective cohort study14 assessed the time-
dependent effect of macrolide therapy versus that of penicillin therapy on the risk of 
hospitalization due to cardiovascular disease. The authors concluded that the decreased 
relative risk of hospitalization (0.48) due to cardiovascular disease in users of macrolides 
within 3 months indicated a possible direct anti-inflammatory effect on diseased vessels, 
but this was not further studied. In several prospective intervention studies using either 
azithromycin (AZ) or roxithromycin, the anti-inflammatory effect was examined. Gupta et 
al.15,16 performed the first intervention trial in which 60 survivors of acute myocardial 
infarction with persistently elevated antichlamydial antibody titers were treated with a 3-
day course of AZ, followed by a single dose per week for 3 months, or with a placebo. In 
a subgroup of patients treated with a double dose of AZ, significant decreases in total 
monocyte tissue factor and CD11b were found after 6 months (but not 3 months). This 
indicates a stronger anti-inflammatory effect after 6 months when a double dose of AZ 
was used. However, no significant differences were noted in the levels of any of the 
inflammatory markers in either of the normal groups receiving AZ or placebo. In a similar 
study by Gurfinkel et al.17, 202 patients with coronary heart disease were treated with 
roxithromycin for 30 days. CRP levels decreased in both the placebo and the 
roxithromycin treatment groups at 30 days, but the declines did not reach statistical 
significance. Moreover, CRP was not associated with the significant reduction in 
ischemic events. This result indicates that the reduction in cardiovascular events in these 
studies is based on a stabilizing effect on atherosclerotic plaques, caused by an 
antichlamydial effect, rather than on an anti-inflammatory effect. 
More recently, Anderson et al.13 treated 302 patients who had coronary artery 
disease and a seropositive reaction to C. pneumoniae with AZ or placebo (in a similar 
treatment protocol as that described by Gupta et al.15,16). The levels of four inflammatory 
markers were unchanged at 3 months but showed minor changes after 6 months. The 
changes in the levels of inflammatory markers before and after treatment were 
significantly lower for CRP (p = 0.011) and IL-6 (p = 0.043) after 6 months (not after 3 
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months). It must be stressed that no difference was found in clinical events and that 
these results are based on minor changes; a major anti-inflammatory effect was not 
shown. The overall minor changes in inflammatory markers are consistent with our study 
results. 
The duration of treatment could be of critical importance in explaining the 
different results in various studies. Our study patients were treated, on average, with 16 
tablets (a number equivalent to the number of treatment days). We therefore repeated 
our analysis on a subgroup of 114 patients who were treated with 14 or more tablets, but 
we found no differences in levels of inflammatory markers between the two groups at 
visit 1, 2 or 3. A repeated analysis of a small subgroup of 56 patients treated with 21 or 
more tablets also did not show any differences. For that reason we can conclude that the 
possible anti-inflammatory effect of clarithromycin, if any at all, does not increase with 
the duration of treatment. In addition, in the intervention studies mentioned above, even 
though patients received long-term treatment for 1 to 3 months13,15,16, such treatment had 
little or no effect on inflammatory markers. Other data about a difference between the 
effects of short-term and long-term administration of macrolides on the immune 
response have been reported in a review by Labro12. These studies are, however, mainly 
ex vivo studies, so comparison to the results with our study population is not appropriate. 
In conclusion, several studies have demonstrated an anti-inflammatory effect of 
macrolides in vitro and in treatment of diseases involved with the bronchial 
epithelium18,19,20. The present study is, however, in our opinion the first reported in vivo 
study about the effect of clarithromycin in patients with atherosclerosis and indicates that 
clarithromycin has no measurable anti-inflammatory effect in such patients. 
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SUMMARY 
 
Recently, Chlamydia pneumoniae has been identified to play a possible role in the 
pathogenesis of atherosclerosis. We investigated whether treatment with clarithromycin 
prior to coronary artery bypass graft surgery (CABG) would prevent subsequent 
cardiovascular events and mortality. 
473 patients, who were scheduled for CABG, were randomly assigned to receive either 
clarithromycin (CL) or placebo (PB) until the day of surgery in a double-blind trial. 
Duration of treatment was on average 16 days. During the 2 years follow-up, mortality 
and cardiovascular events were assessed. Follow-up at 2 years could be achieved in 
89.6 % of all patients. Baseline patient characteristics were well balanced between the 
two treatment groups. Mortality was equal in both groups: 5 (2.4%) in the CL-group and 
6 (2.8%) in the PB-group (relative risk (RR), 0.87; 95% CI, 0.27 to 2.79; p=0.81). Also, 
there were no significant differences in cardiovascular event rates during the follow-up 
period (RR 0.91; 95%CI, 0.50 to 1.64; p=0.86). The overall event rate was 10.6%. 
Treatment with clarithromycin in patients scheduled for CABG did not reduce the 
subsequent occurrence of cardiovascular events or mortality during a 2-year follow-up.  
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INTRODUCTION 
 
It is generally acknowledged that atherosclerosis can be considered partly an 
inflammatory disease. It may result from an immune response to various inflammatory 
stimuli, leading to atherogenesis and coronary artery disease (CAD) progression1. 
Common chronic infections, caused by viruses and bacteria, may contribute to this 
inflammatory process and interact with classical cardiovascular risk factors such as 
smoking, hypercholesterolaemia, diabetes mellitus, hypertension and a positive family 
history of CAD1,2. To date Chlamydia (C.) pneumoniae is the leading potential 'culprit' 
infectious agent with the strongest evidence linking infection and atherosclerosis3. 
Seroepidemiological studies, detection of the organism within atherosclerotic vascular 
tissue (culture, electron microscopy, antigen and DNA detection techniques), in vitro 
experiments and animal models have supported a potential role for this micro-organism 
in the pathogenesis of atherosclerosis4,5. Recently, studies on the reliability of molecular 
detection methods have raised serious questions regarding the interpretation of previous 
studies6. Therefore, the exact role of C. pneumoniae remains to be determined. The 
chain of evidence could be strengthened by studying the effect of antibiotic treatment on 
clinical outcome in patients with CAD.  
World-wide interest was generated by the positive results of two smaller studies 
published in 19977,8, which showed a better outcome after treatment with a macrolide. 
The purpose of the present study was to determine the effect of treatment with the 
macrolide antibiotic clarithromycin prior to coronary artery bypass graft surgery (CABG) 
on clinical outcome and prognosis in patients with severe atherosclerosis in a double-
blind, randomised, placebo-controlled study. 
 
 
METHODS 
 
Patients. Between July 1999 and July 2001, patients with documented coronary 
artery disease were enrolled in the study. All patients were scheduled for coronary artery 
bypass graft (CABG) surgery. Inclusion was carried out during attendance of the pre-
operative outpatient clinic at the department of thoracic surgery of the Amphia Hospital.  
Exclusion criteria were: participation in another study, concomitant administration 
of terfenadine, rifabutin, cisapride or antipyrine; antibiotic therapy with a macrolide, 
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tetracycline, or quinolone within three months prior to inclusion or during the study 
period; the presence of renal failure (serum creatinine rates above 150 µmol/l), elevated 
liver function (ALAT > 55 U/l, ASAT > 45 U/l, total bilirubin > 27 µmol/l, alkaline 
phosphatase  > 180 U/l), female patients capable of child-bearing but not taking 
adequate birth control precautions. 
The study was approved by the local Medical Ethics Committee. 
The research physician saw all patients during their visit to the preoperative 
outpatient clinic, examined their patient files, interviewed them and asked for informed 
consent. Patients were randomised in a double-blind, placebo controlled study. The 
study medication consisted of either a daily dose of clarithromycin 500 mg slow release 
(CL) or a placebo tablet (PB). Clarithromycin SR and matching placebo tablets were 
obtained from Abbott laboratories, (Abbott Laboratories Ltd, Queenborough, Kent, 
England ME11 5EL). Treatment duration was from randomisation until day of surgery. 
An independent pharmacist dispensed either CL or PB tablets according to a 
computer generated randomisation table, which stratified patients in groups of 10. The 
research physician responsible for seeing the patients allocated the next available 
number on entry into the trial, and each patient received the corresponding tablets 
directly from the researcher. The code was revealed to the researcher after the 2.5 years 
of follow-up was completed 
Outcome data. Data on clinical outcome and cardiovascular events were collected 
by the research physician by telephone interview of each patient at 6 and 12 months 
after cardiac surgery, and by interviewing the general practitioner at the end of the 2 
years of follow-up. The primary end point was overall mortality. Secondary end points 
were: reappearance of angina pectoris, myocardial re-infarction, percutaneous coronary 
re-intervention or coronary artery bypass surgery, stroke, and peripheral artery disease 
that required bypass or percutaneous intervention. 
 
Statistical analysis.  
 All base-line characteristics were analysed with a χ2-test or a Student’s t test 
when appropriate. Statistical analysis was performed using SPSS, version 11.0. 
Statistical significance was accepted when P<0.05. 
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Figure 1. Trial profile. 
 
 
RESULTS 
 
Between July 1999 and July 2001, 641 patients were seen at the pre-operative 
outpatients’ clinic. The trial profile (figure 1) shows that 473 patients were enrolled in the 
641 total eligible patients  
473 randomly allocated 
168 excluded 
 30 other surgical procedure 
 22 did not understand the study protocol 
 52 refused participation 
29 use of macrolides, quinolones, or 
tetracyclines ≤ 3 months ago 
 22 participated in other trials 
   2 liver disease (elevated liver enzymes)
   7 renal disease (elevated kreatinin) 
238 clarithromycin 235 placebo 
11 concomitant use of other 
antibiotics 
 
208 analysed for primary 
outcome 
4 concomitant use of other 
antibiotics 
4 other therapy than CABG 
216 analysed for primary 
outcome
16 elective termination 
2 died before surgery 
1 pre-operative stroke 
7 elective termination 
2 died before surgery 
2 pre-operative stroke 
219 completed treatment 224 completed treatment 
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study. Complete follow-up data were obtained on 424 patients. Finally, 208 patients of 
the CL group and 216 patients of the PB group were analysed. 
Table 1 shows that the patient characteristics were well balanced between the 
two treatment groups. No significant differences were found. Patients were treated on 
average for 16 days. There were no significant differences in the event rates during the 
follow-up period, which is shown in table 2. Total mortality was almost equal for both 
treatment groups: 5 (2.4%) in the CL group and 6 (2.8%) in the PB group (relative risk, 
0.87; 95% CI, 0.27 to 2.79; p=0.81). If only patients were analysed who had been treated 
for 21 days or more (138 patients), event rates were also not different between the 
treatment groups (total mortality 3 (5.1%) in CL and 1 (1.5%) in PB group). 
 
Table 1. Baseline patient characteristics and medical history. 
 Clarithromycin (n=208) 
Placebo 
(n=216) 
Baseline characteristics Mean SD  Mean SD 
Age 64.6 8.8 64.0 10.9 
Weight 82.3 13.5 81.1 14.3 
Length 172.1 11.5 171.0 11.0 
NYHA-scorea 2.85 0.8 2.88 0.8 
Number of treatment days 16.0 7.9 16.6 7.7 
 Number  % Number  % 
Sex (male) 166  78.8 169  78.2 
Smoker (currently) 43  20.7 42  19.4 
Medical history     
Smoker in past 119  57.2 130  60.2 
COPDb 21  10.1 22  10.2 
Diabetes Mellitus Type I 12  5.8 13  6.0 
 Type II 18  8.7 25  11.6 
Hypercholesterolaemia 123  59.1 136  63.0 
Malignancy 10  4.8 6  2.8 
Stroke 17  8.2 16  7.4 
Angina pectoris  200  96.2 214  99.1 
Myocardial infarction 107  51.4 104  48.1 
Heart valve insufficiency 7  3.4 3  1.4 
Hypertension 81  38.9 90  41.7 
Earlier vascular surgery 47  22.6 47  21.8 
Family medical history     
Cardiovascular disease  161  77.4 157  72.7 
Diabetes mellitus 31  14.9 32  14.8 
Medication     
Statins 128  61.5 143  66.2 
Anti-hypertensive drugs 208  100 215  99.5 
     
All baseline characteristics were not significantly different between the treatment groups 
a angina pectoris score by classification of the New York Heart Association 
b Chronic Obstructive Pulmonary Disease 
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Table 2. Clinical Events during 24-month follow-up. 
Events Clarithromycin (n=208) 
Placebo 
(n=216) 
P 
 
Relative Risk 
(95% CI) 
     
Death 5 (2.4%) 6 (2.8%) 1.0 0.87 (0.23 - 3.15) 
     
(Unstable) angina pectoris 7 (3.4%) 11 (5.1%) 0.52 0.66 (0.24 - 1.80) 
Nonfatal MI 1 (0.5%) 3 (1.4%) 0.64 0.35 (0.01 - 3.67) 
Revascularizationa 8 (3.8%) 4 (1.9%) 0.35 2.08 (0.58 - 8.11) 
     
Overall cardiac events 16 (7.6%) 18 (8.3%) 0.95 0.92 (0.46 - 1.85) 
     
Stroke 8 (3.8%) 3 (1.4%) 0.20 2.77 (0.68 - 13.05) 
Peripheral vascular surgery 1 (0.5%) 2 (0.9%) 1.0 0.52 (0.02 - 7.21) 
     
Sternal wound infection 1 (0.5%) 1 (0.5%) 1.0 1.04 (0.03 - 37.76) 
     
a Percutaneous coronary intervention or coronary bypass surgery 
 
 
DISCUSSION 
 
Treatment of patients with CAD with a daily dose of 500 mg clarithromycin SR for 16 
days on average prior to cardiac surgery (CABG) did not reduce rates of mortality nor 
cardiovascular events during two years after surgery. A course of clarithromycin in 
patients with severe atherosclerosis appears therefore to be of no clinical value. 
Randomized controlled trials have been performed to analyze the effect of 
treating patients with CAD and its associated complications with antibiotics that have 
activity against C. pneumoniae. These trials were undertaken after several investigators 
found an association of C. pneumoniae with CAD. This association was first noted in 
1988 by Saikku et al in Finland9. Further interest in the association was mainly based on 
the results of seroepidemiological studies, although not all studies or cohorts have found 
a significant relationship after correcting for confounders10. More evidence was gathered 
when the presence of C. pneumoniae in some atherosclerotic lesions was shown. Also 
animal model experiments suggested C. pneumoniae-induced atherogenesis4,5,11. 
Since the promising results of two smaller clinical treatment studies in 19977,8, 
several larger intervention trials have been performed (table 3). Thus far, the significant 
effects in some small clinical trials 7,8,12,13 have not been confirmed by large randomized 
trials14-20,29, including the results found in our study. Antibiotic treatment regimes and 
duration of follow-up varied significantly between the studies, as well as the size and 
type of the study populations (table 3). Nevertheless, the majority of randomised-
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controlled trials did not show any beneficial effect in outcome after a course of 
macrolides in patients with established coronary artery disease.  
There are several possibilities why we did not detect a significant difference 
between the two groups. The duration of treatment in our study might have been too 
short and therefore not effective enough. In the CLARIFY study, Sinisalo et al. 
administered clarithromycin for 3 months on patients with acute non-Q-wave infarction or 
unstable angina and reduced the risk of subsequent cardiac events by 41%12. Other 
trials do not indicate that the duration of treatment is an important item (table 3). 
Especially the WIZARD study, with 7747 patients the largest study by far, treated for 77 
days and did not find a significant effect19. When, in our study, a subgroup of patients 
treated for 21 days was analysed, no difference was found. Therefore, it is unlikely that 
the duration of treatment played an important role. 
The power of the study could also be a point of discussion. However, there was 
no trend towards a better or worse outcome. The most important variables, being 
mortality and all cardiac events, were nearly equal in both groups. Also other large 
studies like AZACS18 and WIZARD19, which included 1439 and 7747 patients 
respectively, did not detect a reduction in cardiovascular events. 
Duration of follow-up and type of antibiotic also seem of no significant influence 
indicated by contrasting outcome of these clinical trials (table 3). It is remarkable that the 
positive results of smaller clinical trials are not found in the larger ones. Off course this 
could be explained by the fact that they are coincident findings. Smaller trials may have 
studied a more selective population, which indicates that certain groups of individuals 
might benefit from antibiotics. In the WIZARD trial19, analysis within subpopulations 
showed trends toward a favorable effect of antibiotic therapy in men who smoke or who 
have diabetes or hypercholesterolemia. In a post hoc analysis of the ISAR-3 trial21, 
patients with the highest titres of C. pneumoniae antibodies had a reduced rate of 
restenosis if given roxithromycin than if given placebo. In our study, treatment with 
clarithromycin did not differ between patients who have diabetes or have not, and those 
who smoke, or do not.  
The negative results of the majority of recent trails, including ours, challenge the 
hypothesis whether viable C. pneumoniae plays a causal role in the pathogenesis of 
atherosclerosis. This doubt is confirmed by other signals in the research field. In more 
recent studies many investigators have failed to detect C. pneumoniae DNA in vascular 
specimens of patients with atherosclerosis22-26. Major inter-laboratory differences exist, 
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especially concerning false-positivity. Moreover, there is no established reference 
method, which makes it almost impossible to draw clear conclusions about the presence 
of C. pneumoniae in vascular tissue and therefore its association with atherosclerosis6. 
In addition, the results of a recent meta-analysis appear to indicate that there is no clear 
relation between chlamydial IgG and atherogenesis10. Whether infection with C. 
pneumoniae plays a putative role in the development of atherosclerosis needs therefore 
to be questioned. Analysis of the pooled cardiac events of all studies shown in table 3 
did not show a significant effect for macrolide treatment (RR 0.97; 95% CI: 0.89 – 1.06). 
This was the same for the pooled mortality (RR 0.97; 95%CI: 0.82 – 1.16). The results of 
our study are in line with these pooled data. Therefore, at present no recommendation 
for the use of antibiotic therapy for the secondary prevention of atherosclerosis can be 
made. 
Apart from its ability to treat C. pneumoniae infection and to reduce the 
vasotropic infectious burden, an anti-inflammatory effect of macrolide antibiotics is often 
mentioned. However, an anti-inflammatory effect of clarithromycin as measured by the 
levels of cytokines and acute phase proteins was not detected in our study patients, as 
published previously27.  
The use of macrolide antibiotics deserves serious thought. In our study 
population, a treatment of 16 days with clarithromycin caused a marked effect on the 
development of resistance in the oropharyngeal flora that lasted for at least 8 weeks 28. 
Therefore, macrolides should be used only when the indication is clearly established.   
In conclusion, this study shows that treatment with macrolide antibiotics has no 
beneficial effect on mortality, cardiac events and surgical site infection in patients with 
severe atherosclerosis undergoing cardiac surgery. This provides further evidence 
against a causative role of C. pneumoniae in the development of atherosclerosis. The 
relationship between C. pneumoniae and atherosclerosis should be studied in more 
detail before new therapeutic trails are to be performed. 
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SUMMARY 
 
To investigate the effect of clarithromycin slow-release on colonisation and the 
development of resistance in oropharyngeal and nasal flora, a double-blind, randomised 
placebo-controlled trial was performed with 8 weeks follow-up. 
296 patients with documented coronary artery disease were randomised in the pre-
operative outpatient clinic to receive a daily dose of clarithromycin 500 mg, slow-release 
SR (CL) or placebo tablets (PB) until the day of surgery. Nose and throat swabs were 
taken before starting therapy, directly after end of therapy and 8 weeks later. Presence 
and Minimal Inhibitory Concentration (MIC) were determined for oral Haemophilus 
species and nasal Staphylococcus aureus. Quantitative culture on media with and 
without macrolides was performed for the indigenous oropharyngeal flora. In addition, 
genotypical analysis was performed on the macrolide resistant indigenous flora. Basic 
patient characteristics were comparable in the two treatment groups. The average 
number of tablets taken was 15 (SD=6.4). Oropharyngeal carriage of Haemophilus 
species was not affected in either of the treatment groups. Nasal carriage of S. aureus, 
however, was significantly reduced in the CL group (from 35.3% to 4.3%) compared to 
the PB group (from 32.4% to 30.3%; p<0.0001; relative risk (RR), 7.0; 95% CI, 3.1-16.0). 
Resistance to clarithromycin was present significantly more frequently after treatment in 
the CL-group in Haemophilus species (p=0.007; RR, 1.6; 95% CI, 1.1-2.3); also, the 
percentage of patients with resistance to macrolides in the indigenous flora after 
treatment was significantly higher in the CL-group (31% to 69%; p<0.0001; RR, 1.9; 95% 
CI, 1.4-2.5). This persisted for at least 8 weeks. 
This study shows that besides the effective elimination of nasal carriage of S. aureus, 
treatment with clarithromycin SR for approximately 2 weeks has a marked and sustained 
effect on the development of resistance in the oropharyngeal flora for at least 8 weeks. 
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INTRODUCTION  
 
Antimicrobial agents are one of the most useful groups of therapeutic agents 
available today. In fact it is the only group of therapeutic agents which has had a 
measurable effect on overall mortality rates in the population1. Unfortunately, emergence 
of resistance against many agents in almost all human pathogens is now widespread 
and a cause of great concern for future therapeutic effectiveness2. Development of 
resistance has been associated with the use of antimicrobial agents in general2,3. 
In 1956, macrolides were introduced and presented as alternatives to penicillins, 
especially for the treatment of infections due to Gram-positive micro-organisms4. 
Currently, they are recommended as a first-line therapy for adults with community-
acquired pneumonia5. Unfortunately, resistance to macrolides among Streptococcus  
pneumoniae, the most common cause of respiratory tract infections, is increasing6,7. 
There is little doubt that this is mainly the result of the increased use of macrolides.  
Few papers have been published with regard to the effect of macrolides on the 
oropharyngeal flora8-12. Moreover, no placebo-controlled randomised study has been 
performed to study the extent of these effects.  
The current study was performed to quantify the effect of clarithromycin on the 
development of resistance in oropharyngeal and nasopharyngeal flora in individual 
patients. This study was part of an ongoing intervention study in cardiothoracic surgery, 
to study the effects of clarithromycin on the presence of Chlamydia pneumoniae in 
cardiovascular tissue. 
 
 
PATIENTS AND METHODS 
 
Study population. Between July 1999 and July 2001, patients with documented 
coronary artery disease, who were scheduled for coronary artery bypass graft (CABG) 
surgery, were enrolled in the study. Inclusion was carried out during a visit to the pre-
operative outpatient clinic at the department of cardio-thoracic surgery of the Amphia 
Hospital in Breda, The Netherlands. Exclusion criteria included the following: 
concomitant administration of terfenadine, rifabutin, cisapride or antipyrine; antibiotic 
therapy with a macrolide, tetracycline, or quinolone within three months prior to inclusion 
or during the study period. After giving informed consent, patients were enrolled in a 
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double-blind, randomised, placebo-controlled study. From that point on, they started 
taking the study medication until the day of surgery. The study medication consisted of 
either a daily dose of slow-release clarithromycin 500 mg (CL) or a placebo (PB) tablet 
(Clarithromycin SR and matching placebo tablets were obtained from Abbott 
Laboratories, Abbott Laboratories Ltd, Queenborough, Kent, England ME11 5EL).  
An independent pharmacist dispensed either CL or PB tablets according to a 
computer generated randomisation table which stratified in groups of 10. The researcher 
responsible for seeing the patients allocated the next available number on entry into the 
trial, and each patient collected the corresponding tablets direct from the researcher. The 
code was revealed to the researcher once recruitment, data collection, and laboratory 
analyses were complete. 
From each patient a nose swab and 2 throat swabs were obtained on inclusion 
during the pre-operative outpatient visit (visit 1), and on the day of surgery just before the 
operation a second nose swab and 2 throat swabs were obtained (visit 2). A third throat 
swab was taken 8 weeks after surgery (visit 3). These swabs were stored in transport 
medium (Transwab™ or a Venturi Transystem ®) at 4°C until further processing.  
Microbiological analysis. The nasal swabs were cultured on a blood agar 
plate and incubated at 35°C for 48 hours. On days 1 and 2 the plates were examined for 
the presence of Staphylococcus aureus. Putative colonies were identified using standard 
identification methods13. S. aureus strains were deep-frozen in a bead storage system at 
-80°C (Protect, Technical Service Consultants Limited, England) until further testing. 
Throat swabs were cultured on blood agar plates containing 5µg/ml gentamicin and 
chocolate agar plates supplied with a bacitracin tablet (Neo-sensitabs ®, Rosco, 
Denmark). These plates were incubated at 35°C in the presence of 5% CO2 for 48 
hours. On days 1 and 2 the throat culture plates were examined for the presence of 
potential pathogenic micro-organisms, e.g. S. pneumoniae, Haemophilus spp., S. 
pyogenes and Moraxella catharralis using standard identification methods14. All identified 
strains were frozen at -80°C until further testing. 
 Sensitivity analysis. Phenotypical resistance was measured by determining the 
minimal inhibitory concentration (MIC) for clarithromycin using E-test® (AB-Biodisk, 
Sweden) according to the manufacturers guidelines. H. influenzae ATCC 49247 and S. 
aureus ATCC 29213 were included as controls. MIC determination was performed by 
reading at the point of complete inhibition of all growth, including micro-colonies, hazes 
and isolated colonies using a plate microscope. Breakpoint for sensitive versus resistant 
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were determined according to NCCLS guidelines (NCCLS MIC H. influenzae ≥ 32 ul/ml 
is resistant). 
Indigenous flora. Culture and resistance detection for erythromycin of the 
total indigenous oropharyngeal flora was performed for all three throat swabs. The 
swabs were suspended in 1 ml 0.9% NaCl and inoculated onto blood agar plates 
containing 0 and 1 mg/L erythromycin using a spiral plater (Eddy Jet, IUL instruments, 
I.K.S., Leerdam, The Netherlands). Firstly, it was determined whether there were any 
macrolide resistant flora by growth on the erythromycin-containing blood agar. Secondly, 
the percentage of resistant flora was quantitatively determined by dividing the number of 
colonies on erythromycin containing plates by the number of colonies on plates without 
erythromycin (x 100%), to indicate the proportion of macrolide resistance among the total 
oropharyngeal flora.  
To study the mechanism of resistance, strains (viridans streptococci and 
coagulase negative staphylococci) resistant to macrolides were studied for the presence 
of genes by PCR, conferring resistance to macrolides as described previously by 
Sutcliffe et al. and Jensen et al.15-17: erm B (target modification by a ribosomal mutation), 
and mef A/E (macrolide efflux pump mechanism) genes for streptococci and erm A, erm 
C (target modification by a ribosomal mutation) and msr (macrolide efflux pump 
mechanism) genes for staphylococci. Some of these genes are known to occur on 
common mobile genetic elements such as transposons, which facilitate the spread of 
these resistance genes. The transposon family Tn916/Tn1545 is known to also harbour 
erm genes18 and is common among Streptococci. In addition the presence of these 
genes on Tn 916 / Tn 1545 was analysed by PCR19.  
This study was approved by the local Medical Ethics Committee.  
Statistical analysis. For statistical analysis all base-line characteristics were analysed 
using the χ2-test for the distribution of categorical variables and the Student’s t test to 
compare continuous variables. To assess differences in MIC values between the two 
treatment groups and between variables with different standard deviations, a 
comparison was made using the Mann-Whitney U-test. The related samples were 
compared using a Wilcoxon Signed Ranks Test. To determine the correlation between 
the duration of therapy and the development of resistance, linear regression analysis 
was performed. Statistical significance was accepted when P<0.05. 
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Figure 1. Trial profile. 
a Screening of indigenous oropharyngeal flora was performed on a different lab and started on a later date 
than the culture of pathogens 
 
 
RESULTS 
 
Figure 1 shows that a total of 296 patients were enrolled in the study and screened for 
culture of oropharyngeal pathogens. Of these, 219 were also screened for indigenous 
380 total eligible patients  
84 excluded 
 13 other surgical procedure 
   9 did not understand the study protocol 
 23 refused participation 
14 used macrolide, quinolone or tetracycline 
antibiotics ≤ 3 months prior  to inclusion 
 14 participated in other trials 
   2 liver disease (elevated liver enzymes) 
   5 renal disease (elevated kreatinin) 
   4 allergy to macrolides 
296 randomised and 
screened for culture of 
pathogens 
219  patients screened 
for indigenous floraa 
148 placebo
6 excluded from analysis 
because of concomitant 
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143 analysed 
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107 analysed for 
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oropharyngeal flora. After randomisation 148 patients received clarithromycin 500 mg 
SR (CL group) and 148 placebo (PB group) (resp. 109 and 110 for patients screened for 
indigenous oropharyngeal flora). Table 1 shows that the patient characteristics are well 
balanced between the two treatment groups. No significant differences were found. 
Six patients used other antibiotics concomitantly during the study period and 
were excluded from further analysis. Nine patients were excluded from the analysis of 
MIC determination for S. aureus, because the strains were not viable after storage. 
 
Table 1. Patient characteristics. 
 
Baseline characteristics 
Clarithromycin 
(n=148) 
Mean 
SD Placebo 
(n=148) 
Mean 
SD 
Age 64.6 8.4 63.3 8.9 
Body mass index 27.6 3.1 28.3 3.7 
Number of tablets used 14.9 6.4 14.8 6.0 
 Clarithromycin (n=148) % 
Placebo 
(n=148) % 
Sex (male) 112 75.7 118 79.7 
Smoker (currently) 28 9.5 28 9.5 
Smoker in past 79 26.7 90 30.4 
COPD 16 5.4 10 3.4 
Diabetes Mellitus  Type I 7 2.4 9 3.0 
 Type II 11 3.7 19 6.4 
Other underlying disease 11 3.7 5 1.7 
Immunosupressive therapy 5 1.7 2 0.7 
Other antibiotics during 
study period 
5 1.7 1 0.3 
SD = standard deviation  
 
Pathogens. 
The prevalence of S. pneumoniae, S. pyogenes and M. catharralis in throat 
cultures was low. S. pneumoniae was found in five patients before treatment and in five, 
other patients, after treatment. M. catharralis was found five times before treatment, and 
in three other patients after treatment. S. pyogenes was found in two patients before 
treatment, but none after. Before treatment, Haemophilus parainfluenza was the only 
potential pathogen found consistently in the throat and S. aureus in the nose 
(approximately 80% and 35% of patients respectively). 
In table 2 the effect of clarithromycin on oropharyngeal carriage of H. 
parainfluenza, and on nasal carriage of S. aureus is shown. Carriage of H. parainfluenza 
was not significantly affected by clarithromycin therapy. Nasal carriage of S. aureus, 
however, was significantly reduced in the CL group (from 35.3% to 4.3%) compared to 
the PB group (from 32.4% to 30.3%, p<0.0001, RR: 7.0; 95% CI, 3.1 - 16.0).  
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Table 2. Number of patients with nasal carriage of S. aureus and oropharyngeal carriage of 
Haemophilus parainfluenza. 
 Clarithromycin % Placebo % p-value 
S. aureus  
Nasal carriage N=139  N=142 
  
Before therapy 49 35.3 46 32.4 NS 
After therapy 6 4.3 43 30.3 <0.0001 
      
 Clarithromycin % Placebo %  
Haemophilus parainfluenza 
Oropharyngeal carriage  N=143 
 N=147   
Before therapy 117 81.8 117 79.6 NS 
After therapy 104 72.7 110 74.8 NS 
      
NS= not significant 
 
In Figure 2, the percentage of patients with clarithromycin-resistant H. 
parainfluenza strains before and after therapy is shown for both groups. It shows a 
significant increase in resistance in the CL-group and not in the PB-group (p=0.007; RR, 
1.6; 95% CI, 1.1 - 2.3). 
Figure 2. Percentage of clarithromycin-resistant oropharyngeal H. parainfluenzae before and 
after therapy in both treatment groups. 
 
 
Statistical analysis was not performed on MICs of S. aureus due to the small 
number of patients with S. aureus after treatment in the CL-group. 
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Indigenous flora. 
Throat swabs were obtained from 219 patients on visits 1 and 2. A third swab 
was obtained from 169 of these 219 patients. Clarithromycin did not reduce the number 
of CFUs/ml or the total amount of oral flora significantly. 
Figure 3 shows the percentage of patients with macrolide-resistant oropharyngeal 
flora for both the PB- and the CL-group at the three different points in time. In the CL-
group the percentage of patients with macrolide-resistant flora in the first swab was 
identical to the placebo group (34%). Directly after treatment in the CL-group there was a 
significant shift towards more patients with resistant oral flora (p<0.0001; RR 1.9; 95% 
CI, 1.4 - 2.5), which was more or less the same in the third throat swab (p=0.003; RR 
1.6; 95% CI, 1.2 - 2.1). The risk of developing resistance in a subgroup of patients 
without detectable resistance before therapy was started was significantly higher in the 
CL group compared to the PB group (p<0.0001; RR, 6.6; 95% CI, 3.2 - 13.5). 
Figure 3. Percentage of patients with macrolide-resistant gram-positive strains in clarithromycin 
and placebo group. 
 
 
Linear regression analysis showed that there was no significant relation between 
the number of tablets taken and the prevalence of resistance in the CL-group. 
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Quantitative culture was performed to determine in each individual patient with 
resistant flora which percentage of the total oral flora was resistant. In the pre-treatment 
situation (visit 1), the mean percentage of the total flora which was resistant in the CL-
group and PB-group was 3.4% and 2.3% respectively. Immediately after treatment (visit 
2) the mean percentage of the total flora which was resistant rose to 21.1 % in the CL-
group (versus 1.1% in the PB group, p<0.0001). This increase was still present 8 weeks 
later (11.4% versus 2·6%, p<0.0001). 
Resistance genes present before treatment, were not significantly different 
between the treatment groups. However, after treatment a significant rise in erm B was 
seen in the streptococci (p<0.0001; RR, 3.5; 95% CI, 2.0-6.1) as well as a significant rise 
in erm C in staphylococci (p=0.002; RR, 4.5; 95% CI, 1.6-12.8) in the CL group 
compared to the PB group. This difference was still present 8 weeks after treatment. 
More than 90% of the tested macrolide-resistant streptococci contained both macrolide-
resistance genes and Tn916/Tn1545 fragments.  
 
 
DISCUSSION  
 
This is the first double-blind, placebo-controlled randomised study that quantifies the 
effect of an antibiotic on the development of resistance in the oropharyngeal flora. It 
shows that administration of a daily dose of 500 mg of slow-release clarithromycin for 2 
weeks has major effects that are still present 8 weeks later. 
Before patients were included in the study, macrolide resistance was already 
frequently present. About 35% of patients carried H. parainfluenzae strains that were 
clarithromycin-resistant and about 35% of the patients had some macrolide-resistant 
indigenous flora. This despite the fact that patients who had recently (≤ 3 months before 
inclusion) been treated with macrolides had been excluded from the study. Whether this 
rate of resistance is due to macrolide therapy in the more distant past (>3 months) or 
whether it is the normal rate in the oropharyngeal flora in this population is not clear.  
Immediately after treatment the percentage of patients with macrolide-resistant 
flora in the CL-group more or less doubled: this was found for both macrolide resistant H. 
parainfluenzae as for macrolide-resistant indigenous oropharyngeal flora. This effect on 
the indigenous flora was even greater if only the group of patients were taken into 
consideration that did not carry macrolide-resistant flora. The relative risk of developing 
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macrolide resistance in the indigenous flora directly after treatment in this group was 6.6 
(95% confidence Interval: 3.2-13.5). 
Unexpectedly, this effect was more or less the same 8 weeks later. Other 
investigators found that emergence of resistance after clarithromycin therapy had 
disappeared after 6 weeks20. In that study another group of patients was treated with 
azithromycin. In this group the resistance rate after 6 weeks was even higher than after 
one week. The authors speculate that this difference is caused by the extremely long 
elimination half-life of azithromycin compared to clarithromycin, which leads to sub-
inhibitory concentrations for several weeks. In our study clarithromycin was used in a 
slow-release form, with a prolonged elimination half-life for once daily dosing (5.3 hrs, 
compared to 2.7 hrs for the normal formula). Although this half-life is not as long as that 
of azithromycin (up to 72 hrs) it is possible that the prolonged effect of clarithromycin SR 
on resistance is partly caused by this prolonged half-life. A big difference however is that 
we were studying patients with gram-positive resistant indigenous flora and H. 
parainfluenzae, whereas Kastner and Guggenbichler were studying specific pathogens 
that are not considered to be part of the normal oropharyngeal flora, such as 
Enterobacter spp., Klebsiella spp. and Pseudomonas spp. 
 Since we anticipated that the effect of CL after 8 weeks would have largely 
disappeared, we did not plan a follow-up beyond that point. Considering our findings, a 
further follow-up would have been useful. Nevertheless, the conclusion is justified that a 
significant and sustained effect on resistance is produced by clarithromycin SR for at 
least 8 weeks. 
Furthermore, the percentage of resistance in the total flora in each individual 
patient was quantified and very low percentages of resistant flora could be detected with 
the method used. To check for the effect of the duration of treatment, an analysis that 
compared the duration of treatment with the percentage of resistant flora was performed. 
No association was found. This finding supports the hypothesis that development of 
resistance was mainly caused by selecting macrolide-resistant isolates, because they 
were already detected after a few tablets. This was also suggested by Leach et al. who 
concluded that the selective effect of macrolides allowed the growth and transmission of 
pre-existing macrolide-resistant strains21. The favorable circumstances for macrolide-
resistant flora is illustrated by the fact that more patients had high proportions of the total 
flora being resistant directly after therapy, compared to the pre-treatment situation. 
Although these high proportions decreased slightly after 8 weeks, the percentage of 
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patients with detectable resistance was still as high as immediately after therapy. This is 
particularly worrying as our results indicate that the resistance genes are associated with 
mobile genetic elements, which facilitate the spread of these genes to more pathogenic 
flora as well. 
Another clear effect of clarithromycin was the effect on the distribution of the 
different resistance genes in the oropharyngeal streptococci and staphylococci. A 
significant rise of the erm B gene (which encodes for target modification) was detected in 
streptococci as well as a significant rise of the erm C gene in staphylococci. Target 
modification due to a mutation of 23S rRNA or ribosomal protein, was the most 
frequently found resistance mechanism in the oropharyngeal flora after CL-therapy, 
which was also found by other investigators 15-17.  
In conclusion, there was substantial development of resistance that was long-
lasting. These findings deserve serious consideration when macrolides are used, 
especially when this is for indications other than infectious diseases. For example, 
erythromycin is known for the treatment of gastroparesis as a gastrointestinal prokinetic 
agent administered orally or intravenously22. Also anti-inflammatory and 
immunomodulatory properties are mentioned in various pulmonary situations such as 
diffuse panbronchiolitis (DPB)23. Given the major effect on the development of resistance 
in the indigenous and pathogenic flora, one should reconsider prescribing macrolides 
and weigh these results against the evidence of the suggested gain. 
Finally, nasal carriage of S. aureus was significantly decreased. In general, 
systemic antibiotic treatment affects the balance between commensal and pathogenic 
microflora, but very few are capable of decreasing the carriage of S. aureus. A study by 
Yu et al., for example, showed a decrease in nasal carriage after administration of 
rifampicin24. Our study showed that clarithromycin SR is capable of decreasing 
staphylococcal nasal carriage from 35.3% to 4.3%, which is comparable to the activity of 
mupirocin nasal ointment25. Eradication of S. aureus is important, because elimination of 
nasal carriage has been found to reduce infection rates and the severe consequences of 
infection in patients at risk26. However, because of the development of resistance, the 
use of macrolides for this indication is questionable. 
In conclusion, our study documents that administration of clarithromycin SR 
results in a significant elimination of S. aureus nasal carriage, but on the other hand 
induces a rapid and prolonged increase in macrolide resistance in oropharyngeal flora. 
The macrolide-resistance genes are similar to those usually detected in pathogenic flora. 
CLARITHROMYCIN AND EMERGING MACROLIDE RESISTANCE 
 99
This study provides indisputable evidence that treatment with clarithromycin results in a 
major effect on the sensitivity of the oropharyngeal flora to macrolides for at least 8 
weeks.  
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SUMMARY and CONCLUSIONS 
 
In 1988 observational evidence for a possible association of C. pneumoniae with 
coronary artery disease (CAD) was first described1. Since then, efforts have been made 
to determine the pathogenic role of C. pneumoniae in atherosclerosis. Several types of 
evidence have suggested this role, derived from seroepidemiological studies, direct 
identification of C. pneumoniae in atherosclerotic lesions, in vitro experimental studies, 
animal model experiments and antibiotic treatment trials in patients with CAD. 
Initially, seroepidemiological studies indicated that patients with CAD had a high 
anti-C. pneumoniae antibody titer, although more recent studies have challenged this2,3. 
It is uncertain whether antibodies to C. pneumoniae reflect active infection, past 
infection, chronic infection, or antigenic cross-reactivity. The conflicting results between 
serological studies are possibly due to lack of uniformity in methods used (different 
classes of antibodies tested, different methods, different cutoff points, cross-reaction to 
non-C. pneumoniae antigens4,5,6). In several retrospective studies no adjustment for 
confounding factors, such as important CAD risk factors was done. Finally, the high 
prevalence of C. pneumoniae exposure in the population makes it difficult to identify true 
differences between those who are actively infected and those who are not. 
In addition to serology, data from basic laboratory studies have provided 
evidence for the presence of C. pneumoniae in atherosclerotic lesions. Direct detection 
of organisms by immunohistochemistry (IHC), electron microscopy, in-situ hybridization, 
or amplification of chlamydial DNA by polymerase chain reaction (PCR) has shown that 
C. pneumoniae can be found in atheromas. Subsequently, viable organisms have been 
detected by amplification of mRNA transcripts from atheromas or have been isolated by 
culture from atherosclerotic tissue. Chapter 2 describes a pilot study that was conducted 
to identify the presence of C. pneumoniae in Dutch patients from our region. C. 
pneumoniae DNA was detected by PCR in 22% (10/45) of the atherosclerotic samples 
and in 10% (5/50) of non-atherosclerotic samples. IHC staining was positive for C. 
pneumoniae in 60% (25/42) of the atherosclerotic specimens and in 9% (4/46) of the 
non-atherosclerotic specimens. The correlation between the detection of C. pneumoniae 
by PCR and IHC was 0.35 (p=0.003) for atherosclerotic specimens. A poor correlation of 
0.1 (p>0.05) was found between these detection techniques in non-atherosclerotic 
specimens. Overall, these study results support the finding of a high prevalence of C. 
pneumoniae in atherosclerotic lesions, when detected by IHC or PCR. Data collected 
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from 43 studies by Kalayoglu et al, indicated a high prevalence of C. pneumoniae (46% 
of 1852) in atheromatous tissue specimens, but a low prevalence of less than 1% in 
healthy arteries7.  
In a second study, we determined the correlation between C. pneumoniae 
serology and the presence of C. pneumoniae as detected by PCR and IHC. As 
described in chapter 2, this correlation appeared very poor. Several other studies have 
reported the same: C. pneumoniae serology frequently does not correlate with the 
identification of the organism by PCR or IHC8. The reliability of anti-chlamydial IgG titers 
for predicting the intravascular presence of the pathogen can therefore be questioned2,3. 
A limitation of chapter 2 is that we did not use established guidelines for the 
interpretation of agreement between tests9. According to these guidelines, the 
agreement between PCR, IHC, and serology found in our study and in most studies 
reviewed in chapter 2 is just fair. In contrast, Juvonen and Shor, found a good correlation 
between the different diagnostic techniques10,11. This latter reanalysis weakens the 
conclusions that we have drawn in chapter 2 and stresses the importance of 
interpretation of the detection methods of C. pneumoniae, and its limitations.  
Increasing interest in the potential link between atherosclerosis and C. 
pneumoniae infection has led to many studies involving C. pneumoniae detection by 
PCR. Because PCR was potentially an important tool for further studies in this field, 
many investigators have used this method, but the results reported so far are 
contradictory and confusing. A considerable variation in the detection rate of C. 
pneumoniae, ranging from 0 % to 100%, has been reported by different investigators. 
The detection varies depending on the methods used but also when independent 
investigators use similar methods. A multi-centre study showed major interlaboratory 
differences in the detection rate of C. pneumoniae in endarterectomy specimens12. 
Obviously, standardization of the detection methods is needed for optimal C. 
pneumoniae identification.  
 In order to efficiently extract DNA from vascular tissue and establish an optimal 
sensitivity of C. pneumoniae identification by PCR, four procedures for C. pneumoniae 
DNA extraction from vascular tissue were compared in chapter 3. Evaluation was based 
on the yield of recovered DNA, using PCR to detect C. pneumoniae in vascular tissue. 
The QIAamp DNA MiniKit was found to be a useful and most efficient extraction method, 
compared to the NucliSens Kit, the buffer-saturated phenol method and the Geneclean II 
Kit. It also had a short handling time, but was more expensive. It should be mentioned 
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that spiked materials and non-spiked atheroma specimens are similar but not absolutely 
identical12, and that it is not known whether the capacity of these different methods to 
extract C. pneumoniae DNA from spiked materials is the same as the capacity to extract 
DNA from patient materials. In our hands, the QIAamp DNA MiniKit was the most 
efficient method, therefore this method for DNA extraction was used in all further studies 
described in this thesis. 
 Since initial seroepidemiologic studies and detection studies showed a clear 
association between C. pneumoniae and augmented atherogenesis, antibiotic 
intervention trials were initiated. The underlying rationale is that antibiotics effective 
against C. pneumoniae may lower the risk for subsequent cardiac events in patients with 
CAD, by eradicating the organism from plaques, thus stabilizing the lesions13. Gupta et 
al. were the first to find a significant risk reduction of cardiovascular events after a short 
(3- to 6-day) course of azithromycin treatment in 220 male survivors of myocardial 
infarction with anti-C. pneumoniae antibody titers14. These promising results prompted 
us to conduct a prospective, randomized, placebo-controlled intervention trial in patients 
with severe atherosclerosis. The objective of this trial was to examine the effects of 
clarithromycin in patients with documented coronary artery disease. Patients who were 
scheduled for coronary artery bypass graft surgery (CABG) were included in the 
intervention trial. All patients were randomly assigned to receive either clarithromycin 
(500 mg SR) or placebo until the day of surgery. 
In chapter 4, the effect of treatment with clarithromycin on the presence of C. 
pneumoniae in vascular tissue and on antibodies against Chlamydia in serum was 
assessed. Despite the use of different detection methods, no evidence for the presence 
of viable C. pneumoniae in vascular tissue of CAD patients could be found. 
Clarithromycin treatment of CAD patients had neither an effect on the presence of C. 
pneumoniae antigens in vascular tissue nor an effect on circulating Chlamydia IgG 
antibody titers.  
Vascular specimens were tested by an automated real-time PCR, and an industry-
developed LCx-C. pneumoniae PCR. However, with both methods we failed to detect C. 
pneumoniae DNA in any specimen. This indicates that there is no evidence of acute C. 
pneumoniae infection in vascular tissue of CAD patients. Other possible explanations for 
the negative results of the PCR assays could be the low DNA concentration in the test 
samples and the patchy distribution of C. pneumoniae DNA in vascular tissue15.  
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In the present study an automated real-time PCR was used, which combines 
amplification, hybridization and quantitative product detection. Lately, many research 
groups have switched to this new, real-time based PCR technology, which is less prone 
to contamination16-18. In earlier studies conventional PCR assays were used. It is 
noteworthy that the rate of positivity of the PCR at our laboratory became lower, as more 
laboratory experience was gained in the molecular assays of C. pneumoniae. Also, 
multicenter studies demonstrated inter- en intra-laboratory discrepancies in the detection 
of C. pneumoniae. Altogether, these findings imply that the results generated by 
conventional PCR assays, including those from our studies, are probably biased by 
inexperience, choice of DNA polymerase, as well as contamination and cross-
reactivity8,19.  
Whereas (real-time and industry developed) PCR assays were negative in all 
specimens, we could detect C. pneumoniae MOMP antigen in the majority of the 
specimens by IHC (73.8% in the clarithromycin group vs. 77.0% in the placebo group), 
but Chlamydia LPS antigen was found in only one specimen. The abundance of MOMP 
in complete absence of C. pneumoniae DNA is also described by other 
investigators8,20,21. It is possible that MOMP antigens of C. pneumoniae might persist for 
a longer period of time, while C. pneumoniae DNA and LPS may degrade more rapidly in 
vascular tissue. Clarithromycin treatment did not have any influence on MOMP antigen 
detection in the atherosclerotic lesions, which further corroborates the notion that this 
antigen can remain unaltered for longer periods. This has also been demonstrated in an 
animal experiment in which antibiotic treatment with azithromycin did not lead to 
elimination of chlamydial antigen from vascular specimens of rabbits infected with C. 
pneumoniae22. Also, in a mice model, azithromycin treatment did not affect the presence 
of C. pneumoniae in the aorta, lung, or spleen23. IHC may allow localization of the 
organisms in specific cells and areas. However, protocols for performance and 
interpretation of IHC are not standardized. This technique requires subjective reading 
and its interpretation remains difficult because of background and nonspecific staining8.  
The results concerning the high detection rate of C. pneumoniae MOMP antigen 
and the low detection rate of C. pneumoniae DNA might be partly explained by the 
biology of chlamydiae. Infections with chlamydiae (e.g. C. trachomatis) are characterized 
by alternate phases of activity and latency followed by fibrosis and scarring24. In 
advanced infections, chlamydiae are no longer viable. The low prevalence or absence of 
C. pneumoniae DNA and LPS in vascular specimens, and the presence of the MOMP 
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antigen supports the theory that there are no viable micro-organisms present in 
advanced atherosclerosis. According to this hypothesis, effects of antibiotic treatment on 
the elimination of Chlamydia from the lesions should be studied in patients in the initial 
stage of atherosclerosis24.  
Apart from an established chemotherapeutic potential, another therapeutic 
potential of macrolide antibiotics might be an anti-inflammatory effect25. Because 
atheromas are characterized by lesions that contain abundant immune cells, particularly 
macrophages and T cells, atherosclerosis can be regarded as an inflammatory disease. 
In addition, C. pneumoniae, as viable or dead organism, may cause a nidus for chronic 
inflammation, in which macrolide antibiotics might work as anti-inflammatory drugs and 
thus reduce cardiovascular risk. Since there was much speculation about the anti-
inflammatory potential of macrolides in patients with CAD, the effect of clarithromycin on 
inflammatory markers was studied (chapter 5). Treatment with clarithromycin for on 
average 16 days did not significantly alter the inflammatory markers C-reactive protein 
[CRP], interleukin [IL]-2R, IL-6, IL-8, and tumour necrosis factor (TNF)-α), nor on the day 
of surgery, nor  8 weeks later. The anti-inflammatory potential of clarithromycin in these 
patients was therefore considered as negligible. In an intervention study with 
roxithromycin in 202 patient with unstable angina or non-Q-wave myocardial infarction 
Gurfinkel et al. found a larger decrease  of CRP in the roxithromycin treatment group 
after 31 days than in the placebo group (p=0.03). However, the CRP base-line levels 
were not associated with major ischemic events26. Anderson et al. found a reduction in a 
composite of inflammatory markers of 302 patients with antibody titers against C. 
pneumoniae after azithromycin treatment27. Although in both studies these results were 
statistically significant, the data were based on minor clinical changes. A clear anti-
inflammatory effect of macrolides in patients with CAD was not shown. 
Since in a few small intervention studies it was found that antibiotic treatment 
might reduce cardiovascular risk in patients with CAD14,28, we performed a follow-up 
analysis of our cohort, to study whether treatment with clarithromycin would prevent 
future cardiovascular events and mortality. A total of 473 patients who were scheduled 
for CABG surgery were finally included in the intervention trial, described in chapter 6. 
Patients were treated for an average of 16 days. Follow-up at 2 years could be achieved 
in 424 out of 473 patients. Total mortality was almost equal for both treatment groups 
(p=0.81). Also, there were no significant differences in cardiovascular event rates during 
the follow-up period (p=0.86). Treatment with clarithromycin in patients scheduled for 
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cardiac surgery did not reduce the subsequent occurrence of cardiovascular events or 
mortality during a 2-year follow-up. A review of all randomised-controlled trials until now 
in patients with established coronary artery disease demonstrated that the majority of 
randomised-controlled trials did not show any beneficial effect in outcome after a course 
of macrolides in these patients. The positive results of small trials14,29,30 were not 
confirmed in larger trials, including ours. One factor might help explain this phenomenon. 
Smaller trials may have been conducted in more selected patient populations, which 
may indicate that certain groups of individuals might benefit from antibiotic treatment. In 
the WIZARD trial, analysis within subpopulations showed trends toward a favorable 
effect of antibiotic therapy in men who smoke or who have diabetes or 
hypercholesterolemia. In the subgroup of patients who had diabetes and smoked the 
event rate was 14.6% for those receiving azithromycin compared to 53% for those 
receiving placebo31. In a subgroup analysis of the ISAR-3 trial, patients with the highest 
titres of C. pneumoniae antibodies had a reduced rate of restenosis if given 
roxithromycin compared to placebo32. In our study results of treatment with 
clarithromycin did not differ for patients who had diabetes or those who had not, and 
those who were smoking, or were not. Therefore, no recommendation for the use of 
antibiotic therapy for the secondary prevention of atherosclerosis could be made. 
The use of antibiotics is associated with the emergence of resistance against 
these agents in almost all human pathogens. This is a widespread problem and cause of 
great concern for future therapeutic effectiveness33,34. Therefore, use of macrolide 
antibiotics such as clarithromycin deserves serious thought when they are used for other 
purposes than infectious diseases such as CAD. Chapter 7 documents the effect of 
clarithromycin on the development of resistance in oropharyngeal and nasopharyngeal 
flora in individual patients, as measured by agar dilution (MIC) and detection of 
resistance genes (MLS) by PCR. Treatment with clarithromycin for 16 days caused a 
major effect on the development of resistance in the oropharyngeal flora, which lasted 
for at least 8 weeks. Immediately after treatment the percentage of patients with 
macrolide-resistant flora in the CL-group more or less doubled (p<0.0001). Furthermore, 
nasal carriage of S. aureus significantly decreased. Because resistance to macrolides is 
increasing35,36, mainly due to the increased use, prescription of macrolides like 
clarithromycin, should be restricted to clear indications. 
Apart from patient-related studies, further evidence for the C. pneumoniae-
atherosclerotic link came from animal model experiments in an attempt to fulfill Koch’s 
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postulates. A problem is that these models are not completely comparable to the disease 
in humans, since animals do not develop atherosclerosis naturally. Therefore animals 
prone to atherosclerosis due to hyperlipemia are used (ApoE mice, low density 
lipoprotein receptor mice, or New Zealand white rabbits). Introduction of C. pneumoniae 
in the respiratory tract simulates the portal of entry in human infection. In these studies it 
was established that C. pneumoniae has particular tropism for the vasculature and the 
capacity to induce inflammation, and that it can initiate or promote lesion development in 
hyperlipemic animals with atherosclerosis37-41. Hu et al, however, found that this 
accelerating effect was correlated to the serum cholesterol level of the animals 38. 
Moreover, compelling evidence for the importance of the hyperlipidaemia and the less 
significant role of Chlamydia, came from severely hyperlipidemic animals that developed 
atherosclerosis in germ-free conditions42. In addition, several infectious agents other 
than C. pneumoniae were shown to be able to induce similar atherosclerotic changes in 
hyperlipidemic animals; therefore there does not seem to be a major atherogenic role for 
C. pneumoniae37,43,44. Also more recent studies have failed to demonstrate a role for C. 
pneumoniae in atherogenesis45,46. Further studies have tested the effects of antibiotic 
treatment in modifying experimental atherogenesis in Chlamydia-infected animals. 
Muhlestein et al first reported that azithromycin prevented accelerated atherosclerosis in 
hyperlipidemic rabbits infected with C. pneumoniae22. More recent observations showed 
that antibiotic treatment was more effective if initiated early after experimental infection 
(< 1 week), which implies that antibiotic treatment has no effect in chronic infections23,47. 
In conclusion, this thesis challenges an active role for C. pneumoniae in 
atherosclerosis. The efforts to demonstrate the presence of C. pneumoniae in vascular 
specimens by several detection techniques have yielded controversial results. 
Unfortunately, available diagnostic methods like PCR and IHC require cautious 
interpretation and standardization to detect or monitor acute, chronic or persistent C. 
pneumoniae infection. Despite the use of several different detection techniques we were 
not able to demonstrate the presence of an active infection with (viable) C. pneumoniae. 
The clinical data of our randomized controlled trial do not support use of antibiotics for 
prevention of cardiovascular events in patients with CAD. Eradication of C. pneumoniae 
could not be demonstrated. An additional anti-inflammatory effect was not shown. Even 
a two years follow-up period did not reveal any difference in the occurrence of 
cardiovascular events in patients treated with clarithromycin or placebo. Moreover, a 
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significant and sustained resistance to macrolide antibiotics was assessed after a 
relatively short-course of clarithromycin.  
We must conclude that the true association between Chlamydia pneumoniae and 
atherosclerosis is still not clear, but we consider a causal role of this micororganism 
highly unlikely because of the complexity and multifactorial nature of atherosclerosis.  
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In 1988 werd een mogelijke associatie tussen C. pneumoniae en coronaire arterieel 
vaatlijden (CAV) voor het eerst experimenteel aangetoond. Sindsdien zijn pogingen 
ondernomen om de pathogene rol van C. pneumoniae in atherosclerose te bepalen. 
Verschillende vormen van bewijs hebben deze rol gesuggereerd, voortkomend uit  
seroepidemiologische studies, de directe identificatie van C. pneumoniae in 
atherosclerotische laesies, in-vitro experimenten, diermodel experimenten en antibiotica 
interventie studies in patiënten met CAV. 
 Aanvankelijk bleek uit seroepidemiologische studies dat patiënten met CAV hoge 
anti-C. pneumoniae antistoftiters hadden, maar meer recente studies betwijfelen dit. Het 
is niet zeker of antistoffen tegen C. pneumoniae een actieve, chronische, in het verleden 
doorgemaakte infectie of antigene kruisreactiviteit weerspiegelen. De tegenstrijdige 
resultaten tussen serologische studies zijn mogelijk gevolg van een gebrek aan 
uniformiteit tussen de gebruikte methoden (verschillende classen van geteste 
antistoffen, verschillende methoden, verschillende grenswaarden, kruisreactiviteit tegen 
niet-C. pneumoniae antigenen). Tevens werd in verschillende retrospectieve studies niet 
gecorrigeerd voor beïnvloedende factoren. Een bijkomend probleem is dat het moeilijk is 
om duidelijk onderscheid te maken tussen actief geïnfecteerden en niet actief 
geïnfecteerden. 
 Naast studies gebaseerd op serologie leverden algemene laboratorium studies 
bewijs voor de aanwezigheid van C. pneumoniae in atherosclerotische laesies. Directe 
detectie van de organismen door middel van immunohistochemie (IHC), electronen 
microscopie, in-situ hybridisatie of amplificatie van chlamydia DNA door middel van 
polymerase ketting reactie (PCR) hebben de aanwezigheid van C. pneumoniae in 
atheromen aan het licht gebracht. Vervolgens zijn levende organismen gedetecteerd 
door amplificatie van mRNA transcripten uit atheromen of geïsoleerd door het kweken 
van delende organismen uit atherosclerotisch weefsel. In Hoofdstuk 2 beschrijven wij 
een pilot studie naar de detectie van C. pneumoniae. C. pneumoniae DNA werd 
gedetecteerd door middel van PCR in 22% (10/45) van de atherosclerotische weefsels 
en in 0% (5/50) van de niet-atherosclerotische weefsels. IHC kleuring was positief voor 
C. pneumoniae in 60% (25/42) van de atherosclerotische monsters en in 9% (4/46) van 
de niet-atherosclerotische weefsels. De correlatie tussen de detectie van C. pneumoniae 
door middel van PCR en IHC was 0,35 (p=0,003) voor atherosclerotische weefsels. Een 
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zwakke correlatie van 0,1 (p>0,05) werd gevonden tussen deze detectie technieken in 
niet-atherosclerotische weefsels. Over het algemeen ondersteunen de studie resultaten 
de bevinding van een hoge prevalentie van C. pneumoniae in atherosclerotische laesies 
wanneer deze aangetoond wordt met behulp van IHC of PCR. Verzamelde data van 43 
studies door Kalayoglu et al toonden een hoge prevalentie van C. pneumoniae (46% van 
1852) in atheromateuze weefsels, maar minder dan 1% in gezonde arteriën. 
Daartegenover vinden wij (hoofdstuk 2) geen correlatie tussen C. pneumoniae serologie 
en detectie resultaten van zowel PCR als IHC. Verschillende andere studies kwamen tot 
dezelfde bevinding dat C. pneumoniae serologie vaak niet correleerde met de 
identificatie van het organisme door PCR of IHC. De betrouwbaarheid van anti-
chlamydia IgG titers in het voorspellen van de intravasculaire aanwezigheid van het 
pathogeen mag daarom worden betwijfeld. Een beperking van de studie die beschreven 
wordt in hoofdstuk 2 is dat we de richtlijnen voor de interpretatie van de correlatie (lees 
overeenkomst) tussen de test methodes niet hebben gebruikt. Volgens deze richtlijnen is 
de overeenkomst tussen PCR en IHC in onze studie en de meeste gereviewde studies 
uit hoofdstuk 2 redelijk. Een goede overeenkomst werd alleen gevonden door de 
Juvonen en Shor et al.. Deze heranalyse zwakt de conclusies uit hoofdstuk 2 enigszins 
af en benadrukt het belang van de interpretatie van de detectie methoden.  
 Toenemende interesse in de potentiele link tussen atherosclerose en C. 
pneumoniae infectie heeft geleid tot vele studies waarbij C. pneumoniae gedetecteerd 
wordt door middel van PCR. Omdat PCR potentiëel een belangrijk hulpmiddel is voor 
aanvullende studies op dit gebied hebben veel onderzoekers deze methode gebruikt. De 
resultaten zijn echter tegenstrijdig en verwarrend. Een aanzienlijke variatie in de C. 
pneumoniae detectie werd gerapporteerd door diverse onderzoekers, variërend van 0% 
tot 100%. De detectie variëerde tussen de diverse gebruikte methoden, maar ook tussen 
verschillende onafhankelijke onderzoekers die vergelijkbare methodes gebruikten. Een 
multi-centre studie toonde aanzienlijke verschillen in het detectie percentage van C. 
pneumoniae in endartherectomie weefsels tussen laboratoria onderling. Het is duidelijk 
dat voor optimale detectie van C. pneumoniae standaardisatie van de detectie methoden 
een absolute voorwaarde is. 
 Om de meest efficiente methode te kiezen voor DNA extractie uit vaatwand 
weefsel en een optimale gevoeligheid te bewerkstelligen voor C. pneumoniae detectie 
door PCR, werden eerst vier C. pneumoniae DNA extractie methoden met elkaar 
vergeleken (hoofdstuk 3). De evaluatie werd gebaseerd op de hoeveelheid vrijgekomen 
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DNA na extractie uit weefsel met verschillende concentraties toegevoegde C. 
pneumoniae, waarbij PCR gebruikt werd om C. pneumoniae te detecteren in vaatwand 
weefsel. De QIAamp DNA MiniKit bleek een nuttige en meest efficiente extractie 
methode, vergeleken met de NucliSens Kit, de verzadigde-buffer phenol methode en de 
Geneclean II Kit. Het had tevens een korte gebruikers tijd, maar was iets duurder. Het 
moet benadrukt worden dat materialen waar DNA aan toegevoegd is vergelijkbaar zijn 
met materialen waarbij dit niet is toegevoegd, maar zeker niet identiek zijn. Het is niet 
bekend of C. pneumoniae DNA extractie uit materialen waar het van te voren kunstmatig 
aan toegevoegd is even efficiënt verloopt  als de extractie van C. pneumoniae DNA uit 
natuurlijk geïnfecteerd patiënten materiaal. Omdat de QIAamp DNA MiniKit in onze 
handen het meest efficiënt was, is deze DNA extractie methode verder gebruikt in alle 
studies beschreven in dit proefschrift. 
 Sinds de veelbelovende resultaten van de eerste seroepidemiologische en 
detectie studies, waarbij het verband tussen C. pneumoniae en toenemende 
atherogenese werd gelegd, zijn antibiotica interventie studies geïnitiëerd. De theorie is 
dat antibiotica die effectief zijn tegen C. pneumoniae het risico op cardiovasculaire 
incidenten bij patiënten met CAV kunnen verminderen, doordat het organisme uit de 
plaque wordt geëradiceerd en daarmee de plaque stabiliseert. Gupta et al. waren de 
eersten die een significante afname van het risico in cardiovasculaire incidenten vonden, 
na een korte behandeling (3 of 6 dagen) met azithromycine. Deze studie werd 
uitgevoerd bij 220 mannelijke overlevenden van een myocard infarct met anti-C. 
pneumoniae antistoftiters. Deze veelbelovende resultaten vormden de aanleiding voor 
een prospectieve, gerandomiseerde, placebo-gecontroleerde interventie studie bij 
patiënten met ernstige atherosclerose in ons centrum. Het doel van deze hoofdstudie 
was de effecten van clarithromycine in patiënten met gedocumenteerd coronair 
vaatlijden te onderzoeken. Patiënten die op de wachtlijst stonden voor coronair arteriële 
bypass chirurgie (CABG) werden geïncludeerd. Alle patiënten werden gerandomiseerd 
om hetzij met clarithromycine (500 mg SR) of met placebo behandeld te worden tot de 
dag van chirurgie. 
 In hoofdstuk 4 beschrijven wij de studie waarin het effect van behandeling met 
clarithromycine op de aanwezigheid van C. pneumoniae in vaatwand weefsel en op 
antistoffen tegen Chlamydia in serum onderzocht werd. Ondanks het gebruik van 
diverse detectie methoden, werd er geen bewijs gevonden voor de aanwezigheid van 
levende C. pneumoniae in vaatwand weefsel van patiënten met CAV. Clarithromycine 
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behandeling van patiënten met CAV had geen effect op de aanwezigheid van C. 
pneumoniae antigenen in vaatwand weefsel, noch een effect op circulerende Chlamydia 
IgG antistof titers. Vaatwand weefsels werden onderzocht met een geautomatiseerde 
real-time PCR en een door de industrie ontwikkelde LCx-C. pneumoniae PCR. Met geen 
van beide methodes konden wij echter C. pneumoniae DNA aantonen in welk van de 
vaatwand weefsels dan ook. Deze studie levert dan ook geen bewijs voor de 
aanwezigheid van een acute C. pneumoniae infectie in vaatwandweefsel van patiënten 
met CAV. Andere verklaringen voor de negatieve resultaten van deze PCR testen zou 
de lage DNA concentratie kunnen zijn in de geteste monsters en de vlekkerige verdeling 
van C. pneumoniae DNA in vaatwand weefsel. 
 In de huidige studie werd een geautomatiseerde real-time PCR gebruikt, die 
amplificatie combineert met hybridisatie en kwantitatieve product detectie. De laatste tijd 
zijn veel onderzoeksgroepen overgeschakeld op deze nieuwe, op real-time gebaseerde 
PCR technologie, die minder vatbaar is voor contaminatie. In eerdere studies werden 
conventionele PCR methodes gebruikt. Het is opmerkelijk dat het percentage van 
positiviteit in ons laboratorium minder werd naarmate meer ervaring werd opgebouwd 
met moleculaire testmethodes voor het aantonen van C. pneumoniae. Ook in muticenter 
studies werden grote inter- en intra-laboratorium verschillen in de detectie van C. 
pneumoniae aangetoond. Deze gezamelijke factoren impliceren dat de resultaten die 
verkregen zijn met conventionele PCR methodes, inclusief die van onze studies, 
waarschijnlijk beïnvloed zijn door onervarenheid, keuze van DNA polymerase, maar ook 
door contaminatie en kruis-reactiviteit. 
 Terwijl de PCR testen negatief waren voor alle weefsels, detecteerden wij met 
behulp van IHC C. pneumoniae MOMP antigenen in de meerderheid van de weefsels 
(73,8% in de clarithromycine groep vs. 77,0% in de placebo groep), maar werd 
Chlamydia LPS antigeen slechts in één weefsel gevonden. Een overdaad aan MOMP 
antigenen in volledige afwezigheid van C. pneumoniae DNA werd ook gevonden door 
andere onderzoekers. Het is mogelijk dat C. pneumoniae MOMP antigenen langere tijd 
in vaatwandweefsel persisteren, terwijl  C. pneumoniae DNA en LPS sneller degraderen. 
Een duidelijke aanwijzing vinden wij het feit dat de behandeling van patiënten met 
clarithromycine geen invloed had op de MOMP antigeen detectie. Hetzelfde werd 
gedemonstreerd in een diermodel experiment, waarbij behandeling met azithromycine 
niet geassociëerd was met de eliminatie van Chlamydia antigenen uit vaatwand 
monsters van met C. pneumoniae geïnfecteerde konijnen. Ook in een muizenmodel had 
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azithromycine behandeling geen effect op de aanwezigheid van C. pneumoniae 
antigenen in de aorta, longen of milt. Met behulp van IHC is het mogelijk om het 
microorganisme in specifieke cellen en gebieden te localiseren. De protocollen voor 
uitvoering en interpretatie van IHC zijn echter niet gestandaardiseerd. Deze techniek 
vereist een subjectieve beoordeling en de interpretatie blijft moeilijk door de 
aanwezigheid van achtergrond kleuring en niet-specifieke kleuring. 
 Het hoge detectie percentage van C. pneumoniae MOMP antigenen en het lage 
detectie percentage van C. pneumoniae DNA in vaatwandweefsel zou gedeeltelijk 
verklaard kunnen worden door de biologie van de chlamydiae. Infecties met chlamydiae 
(bijv. C. trachomatis) worden gekarakteriseerd door afwisselende fases van activiteit en 
inactiviteit, gevolgd door fibrosering en verlittekening. In gevorderde infecties zijn 
chlamydiae niet levend meer. De lage prevalentie of afwezigheid van C. pneumoniae 
DNA en LPS in vaatwand monsters en de aanwezigheid van MOMP antigeen 
ondersteunt de theorie dat er geen levende microörganismen aanwezig zijn in 
gevorderde atherosclerosis. Volgens deze hypothese zou het eradicatie effect van 
antibiotica bestudeerd moeten worden in een beginnend stadium van atherosclerose. 
 Naast een aangetoond chemotherapeutisch vermogen zouden macrolide 
antibiotica een onstekingsremmend effect hebben. Omdat atheromen gekarakteriseerd 
worden door laesies die een overdaad aan immuuncellen bevatten, met name 
macrophagen en T-cellen, kan atherosclerose gezien worden als een ontstekingsziekte. 
Daarnaast zou C. pneumoniae, als levend of dood organisme, een oorzaak kunnen zijn 
van chronische ontsteking, waarbij macrolide antibiotica zouden werken als 
ontstekingsremmende medicatie en zo het cardiovasculaire risico verminderen. Omdat 
er veel discussie is over het ontstekingsremmende vermogen van macroliden bij 
patiënten met CAV, hebben wij het effect van clarithromycine op onstekingsfactoren 
bestudeerd (hoofdstuk 5). De gemiddeld 16 dagen durende behandeling met 
clarithromycine had geen invloed op de niveaus van de onstekingsfactoren CRP, IL-2R, 
IL-6, IL-8 en TNF-α op de dag van chirurgie en 8 weken later. In onze patiëntengroep 
bleek clarithromycine geen ontstekingsremmend effect te hebben. In een interventie 
studie waarbij 202 patiënten met instabiele angina of een non-Q-golf myocard infarct 
werden behandeld met roxithromycine of placebo, toonden Gurfinkel et al. na 31 dagen 
een grotere daling van CRP in de roxithromycine behandelingsgroep in vergelijking met 
de placebo groep (p=0,03) aan. Echter waren deze CRP basis niveaus niet 
geassocieerd met grote cardiovasculaire incidenten. Anderson et al. vonden een daling 
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in de combinatie van onstekingsfactoren bij 302 patiënten met antistof titers tegen C. 
pneumoniae na azithromycine behandeling. Alhoewel de verschillen in beide studies 
statistisch significant zijn, zijn deze verschillen gebaseerd op minimale verandering in de 
waarden van de verschillende ontstekingsmediatoren. Een duidelijk ontstekings-
remmend effect van macroliden in patiënten met CAV werd niet aangetoond. 
 In een aantal kleine interventie studies werd aangetoond dat antibiotica 
behandeling het cardiovasculaire risico bij patiënten met CAV zou verlagen. Wij volgden 
ons cohort patiënten nog gedurende twee jaar na de operatie, om na te gaan of 
behandeling met clarithromycine latere cardiovasculaire incidenten en mortaliteit zou 
voorkomen. In totaal werden 473 patiënten die op de wachtlijst stonden voor CABG 
hartchirurgie uiteindelijk geïncludeerd in de interventie studie, beschreven in hoofdstuk 
6. Patiënten werden behandeld voor gemiddeld 16 dagen. Follow-up na 2 jaar werd 
volbracht voor 424 van de 473 patiënten. De totale mortaliteit was zo goed als gelijk in 
beide groepen (p=0,81). Ook was er geen significant verschil in cardiovasculaire incident 
percentages gedurende de follow-up (p=0,86). Behandeling met clarithromycine in 
patiënten die wachtten op hartchirurgie, verminderde het aantal daarop volgende 
cardiovasculaire events en mortaliteit gedurende 2 jaar follow-up niet. Een review van 
alle gerandomiseerd gecontrolleerde trials (RCT’s) tot nu toe in vergelijkbare patiënten 
toonde aan dat de meerderheid van de RCT’s geen nuttig effect van een macroliden 
kuur in deze patiënten laten zien. De positieve resultaten van kleine trials werden dus 
niet bevestigd door grotere studies, inclusief die van ons. Een mogelijke verklaring zou 
kunnen zijn dat de kleinere trials mogelijk zijn uitgevoerd in meer geselecteerde 
patiëntengroepen wat zou kunnen betekenen dat bepaalde groepen patiënten wel 
voordeel hebben van antibiotica. In de WIZARD studie liet analyse in een subpopulatie 
een trend zien richting een nuttig effect van antibioticabehandeling bij mannen die roken 
of diabetes of hypercholesterolemie hebben. In de subgroep van patiënten die diabetes 
hadden en rookten was het percentage cardiovasculaire incidenten 14,6% voor 
diegenen die azithromycine kregen, vergeleken met 53% voor diegenen die placebo 
kregen. In een subgroep analyse van de ISAR-3 trial hadden patiënten met de hoogste 
titers van C. pneumoniae antistoffen een het laagste percentage restenose na 
behandeling met roxithromycine in vergelijking met placebo. In de in hoofdstuk 6 
beschreven studie bleek behandeling met clarithromycin geen verschillend effect te 
hebben bij patiënten met of zonder diabetes, of die wel of niet rookten. Het gebruik van 
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antibiotica als secundaire preventie van atherosclerose kan ons inziens vooralsnog niet 
worden aanbevolen. 
 Het gebruik van antibiotica in het algemeen is geassociëerd met het onstaan van 
resistentie tegen deze middelen van vrijwel alle menselijke pathogenen. Resistentie is 
een wereldwijd probleem en aanleiding tot grote zorg voor toekomstige therapeutisch 
effectiviteit. Daarom is het van belang serieus na te denken bij het gebruik van macrolide 
antibiotica, zoals clarithromycine, wanneer deze worden toegepast voor andere doelen 
dan de behandeling van infectieziekten. In hoofdstuk 7 wordt het effect van 
clarithromycine op de ontwikkeling van resistentie in de oropharyngeale en 
nasopharyngeale flora van patiënten die deelnamen aan de interventiestudie. 
Resistentieontwikkeling werd gemeten met behulp van agar dilutie (MIC) en door 
detectie van resistentie genen (MLS) met PCR. Zestien dagen behandeling met 
clarithromycine had een aanzienlijk effect op de ontwikkeling van resistentie in de 
oropharyngeale flora en dit effect bleef minstens 8 weken aantoondbaar. Direct na 
behandeling was het percentage patiënten met macrolide-resistente flora min of meer 
verdubbeld (p<0,0001). Bovendien nam dragerschap van S. aureus significant af. Omdat 
de resistentie tegen macroliden reeds aan het toenemen is, hoofdzakelijk door het 
toenemend voorschrijven en gebruik van macroliden, zoals clarithromycine, willen wij er 
voor pleiten dat macroliden alleen gebruikt worden bij duidelijke indicaties. 
 Verder bewijs voor de associatie tussen C. pneumoniae en atherosclerose werd 
geleverd door diermodel experimenten in een poging de postulaten van Koch te 
vervullen. Een probleem is dat een optimaal diermodel niet voor handen is, omdat dieren 
van nature geen atherosclerose ontwikkelen. Daarom worden dieren gebruikt die neigen 
tot atherosclerose door hyperlipidemie (ApoE muizen, low density lipoprotein muizen of 
New Zealand witte konijnen). Introductie van C. pneumoniae in de luchtwegen simuleert 
de porte d’ entrée van infectie bij mensen. In deze studies werd aangetoond dat C. 
pneumoniae een specifiek tropisme heeft voor de vaatwand, de capaciteit heeft om 
ontsteking te induceren en de ontwikkeling van laesies kan initiëren en stimuleren in 
hyperlipemische dieren met atherosclerose. Hu et al. namen echter waar dat dit effect 
gecorreleerd was met het serum cholesterol niveau van deze dieren. Tevens bleek dat 
ernstig hyperlipemische dieren atherosclerose konden ontwikkelen in een bacil-vrije 
omgeving. Een causale rol voor C. pneumoniae wordt door deze bevindingen 
onwaarschijnlijk. Een bijkomstig tegenargument is dat verschillende andere infectieuze 
verwekkers ook de potentie blijken te hebben om vergelijkbare atherosclerotische 
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veranderingen in hyperlipemische dieren te induceren als C. pneumoniae. Aanvullende 
studies hebben het effect van antibioticabehandeling op experimentele atherogenese in 
dieren geïnfecteerd met Chlamydia onderzocht. Muhlestein et al. rapporteerde als 
eersten dat azithromycine atherosclerose voorkwam in hyperlipemische konijnen die 
geïnfecteerd waren met C. pneumoniae. Meer recente observaties laten zien dat 
antibioticabehandeling meer effectief is als deze gestart werd kort na experimentele 
infectie (< 1 week), wat impliceert dat behandeling met antibiotica geen effect heeft bij 
chronische infecties. 
 Concluderend: aan de hand van de door ons behaalde en in dit proefschrift 
beschreven resultaten betwijfelen wij of C. pneumoniae een actieve rol speelt in het 
ontstaan van atherosclerose. De pogingen tot het aantonen van de aanwezigheid van C. 
pneumoniae in vaatwandmonsters met behulp van verschillende detectiemethoden 
gaven controversiële resultaten. Helaas vereisen de beschikbare diagnostische 
methodes als PCR en IHC nauwkeurige interpretatie en standaardisatie om een acute, 
chronische of persisterende C. pneumoniae infectie aan te tonen of te volgen. Het 
gebruik van verschillende detectie technieken leverde geen aanwijzingen voor een 
actieve infectie met (levende) C. pneumoniae. De resultaten van onze gerandomiseerd 
gecontrolleerde studie ondersteunen het gebruik van antibiotica voor de preventie van 
cardiovasculaire events in patiënten met CAV niet. Eradicatie van C. pneumoniae uit 
atheroscelrotische laesies kon niet worden aangetoond. Een ontstekingsremmend effect 
van de macrolide therapie werd niet waargenomen. Zelfs na 2 jaar was er geen verschil 
in het aantal cardiovasculaire incidenten bij patiënten behandeld met clarithromycin of 
met placebo. Bovendien veroorzaakte de relatief korte clarithromycinekuur al significante 
en blijvende resistentie in de orofaryngeale flora van de behandelde patiënten.  
De ware associatie tussen het pathogeen en atherosclerose is nog steeds niet duidelijk, 
maar wij achten een oorzakelijke rol van dit microgorganisme erg onwaarchijnlijk in het 
kader van het complexe en multifactoriële karakter van atherosclerose.  
 

 
 
 
 
 
 
 
PUBLICATIES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PUBLICATIES 
 129
PUBLICATIES 
 
1. Kluytmans J, Berg H, Steegh P, Vandenesch F, Etienne J, van Belkum A. Outbreak of 
Staphylococcus schleiferi wound infections: strain characterization by randomly amplified 
polymorphic DNA analysis, PCR ribotyping, conventional ribotyping, and pulsed-field gel 
electrophoresis. J Clin Microbiol 1998;36(8):2214-2219 
2. Maraha B, van Der Zee A, Bergmans AM, Pan M, Peeters MF, Berg HF, Scheffer GJ, 
Kluytmans JA. Is Mycoplasma pneumoniae associated with vascular disease? J Clin 
Microbiol 2000;38(2):935-936 
3. Berg HF, Brands WG, van Geldorp TR, Kluytmans-VandenBergh FQ, Kluytmans JA. 
Comparison between closed drainage techniques for the treatment of postoperative 
mediastinitis. Ann Thorac Surg 2000;70(3):924-929. 
4. Maraha B, Berg H, Scheffer GJ, van der Zee A, Bergmans A, Misere J, Kluytmans J, Peeters 
M. Correlation between detection methods of Chlamydia pneumoniae in atherosclerotic and 
non-atherosclerotic tissues. Diagn Microbiol Infect Dis. 2001;39(3):139-143 
5. Berg HF, Van Gendt J, Rimmelzwaan GF, Peeters MF, Van Keulen P. Nosocomial influenza 
infection among post-influenza-vaccinated patients with severe pulmonary diseases. Journal 
of Infection 2003; 46(2):129-132 
 
6. Berg HF, Maraha B, Bergmans AMC, van der Zee A, Kluytmans JAJW, Peeters MF. 
Extraction of Chlamydia pneumoniae-DNA from vascular tissue for use in PCR: an evaluation 
of four procedures. Clinical Microbiology and Infection 2003;9(2):135-139   
 
7. Berg HF, Maraha B, Scheffer GJ, Peeters MF, Kluytmans JAJW. The effect of clarithromycin 
on inflammatory markers in patients with atherosclerosis. Clinical and Diagnostic Laboratory 
Immunology 2003;10(4):525-528 
 
8. Maraha B, Berg HF, Kerver M, Kranendonk S, Hamming J, Kluytmans JAJW, Peeters MF, 
van der Zee A. Is the perceived association between Chlamydia pneumoniae and vascular 
diseases biased by methodology? Journal of Clinical Microbiology 2004;in press 

 
 
 
 
 
 
 
 
 
 
DANKWOORD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  132
DANKWOORD 
 
Het is een mooi moment na al die jaren een proefschrift te kunnen tonen. Dit was 
natuurlijk nooit mogelijk geweest zonder de steun van velen om mij heen met wie ik 
gedurende het lange traject van het promotieonderzoek heb samengewerkt. Ik wil de 
belangrijksten hier bedanken. 
 
Allereerst mijn co-promotor dr. J.A.J.W. Kluytmans. Beste Jan, als gevolg van onze 
samenwerking voorafgaand aan mijn co-schappen, was jij degene die me in 1999 
opbelde met de vraag of ik voor de Maatschap Artsen-microbioloog Brabant wilde 
komen werken om een promotieonderzoek op te starten in de toenmalige Klokkenberg. 
Mijn eerste schreden in onderzoek doen en mijn eerste publicatie heb ik aan jou te 
danken. Daarna volgde er meer. Het was fijn om met je samen te werken omdat je altijd 
wel even tijd had om over het onderzoek mee te denken. Ik heb veel van je geleerd, 
door je heldere en kritische blik. Je stimuleerde me ook in mindere tijden door te zetten. 
Je overzicht en visie waren erg verhelderend. 
 
Dr. M.F. Peeters. Beste Marcel, als opleider medische microbiologie in Tilburg en 
landelijk voorzitter van de Nederlandse Vereniging voor Medische Microbiologie heb je, 
materiëel en financiëel, veel ondersteund en voor elkaar gekregen. Je maakte de 
uitvoering van diverse studieonderdelen mogelijk. Voor je gedrevenheid, enthousiasme 
en onuitputtelijke energie heb ik veel respect. Dankzij jou heb ik de mogelijkheid gehad 
de opleiding tot arts-microbioloog te volgen. Ik dank je voor je begrip voor mijn 
uiteindelijke heroriëntatie, en de mogelijkheden die je hebt gecreëerd om het onderzoek 
uiteindelijk af te ronden. 
 
Mijn promotor Prof.dr. C.M.J.E. Vandenbroucke-Grauls. Beste Christina, de uiteindelijke 
samenwerking met jou heeft de voltooiing van dit proefschrift mogelijk gemaakt. Veel 
dank voor je heldere kritiek in de laatste fase. 
 
Uit de beginfase op het thoraxcentrum van de Klokkenberg (heden Amphia Ziekenhuis): 
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